ʻO Octreotide Depot 20 m: nā ʻōlelo aʻoaʻo no ka hoʻohana

Inoa inoa:Octreotide-depo

Ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu ʻana

ʻO ka Lyophilisate no ka hoʻomākaukau ʻana no ka hoʻōla ʻana no ka hana intramuscular i ka hana lōʻihi o ka ʻula keʻokeʻo a ʻulaʻula paha me kahi hiʻi melemele, ma ke ʻano o kahi pauna a i ʻole ka liʻuli i hoʻopiʻi ʻia i loko o kahi pākaukau, ʻo ka hāmeʻa i hoʻopihapiha ʻia he ʻano wai nāpa ʻono ʻole, ʻo ka hoʻopiʻi mākaukau he keʻokeʻo a he keʻokeʻo paha me kahi ʻōpala melemele. homogeneous. 1 ka pahu wai he 10 mg o octreotide. Nā mea kūʻai: copolymer o DL-lactic a me ka glycolic acid - 270 mg, D-mannitol - 85 mg, carboxymethyl cellulose sodium salt - 30 mg, polysorbate-80 - 2 mg.

Haʻalele mannitol, maʻi houake 0.8% - 2 ml.

ʻO ka nui o ka hue wai o nā aniani o 10 ml. Kuhi i ka pahu kipa 1 ampoule o ka solvent, he syringe disable, 2 d / a me nā pono a me nā 2 wai kaona. Hoʻopili ʻia i kahi pahu pepa.

ʻO ka Lyophilisate no ka hoʻomākaukau ʻana no ka hoʻōla ʻana no ka hana intramuscular i ka hana lōʻihi o ka ʻula keʻokeʻo a ʻulaʻula paha me kahi hiʻi melemele, ma ke ʻano o kahi pauna a i ʻole ka liʻuli i hoʻopiʻi ʻia i loko o kahi pākaukau, ʻo ka hāmeʻa i hoʻopihapiha ʻia he ʻano wai nāpa ʻono ʻole, ʻo ka hoʻopiʻi mākaukau he keʻokeʻo a he keʻokeʻo paha me kahi ʻōpala melemele. homogeneous. 1 ka pahu wai he 20 mg o octreotide. Nā mea kūʻai: copolymer o DL-lactic a me nā glycolic acid - 560 mg, D-mannitol - 85 mg, carboxymethyl cellulose sodium salt - 30 mg, polysorbate-80 - 2 mg.

Haʻalele mannitol, maʻi houake 0.8% - 2 ml.

ʻO ka nui o ka hue wai o nā aniani o 10 ml. Kuhi i ka pahu kipa 1 ampoule o ka solvent, he syringe disable, 2 d / a me nā pono a me nā 2 wai kaona. Hoʻopili ʻia i kahi pahu pepa.

ʻO ka Lyophilisate no ka hoʻomākaukau ʻana no ka hoʻōla ʻana no ka hana intramuscular o ka hana lōʻihi o ka ʻula keʻokeʻo a keʻokeʻo paha me kahi ʻāpana puaʻa, a i ke ʻano o kahi pauku a i ʻole ka nui a i hoʻopili ʻia i loko o kahi pālala, ʻo ka hāmeʻa i hoʻopihapiha ʻia he ʻano wai nāpa ʻono ʻole, ʻo ka hoʻopiʻi mākaukau he keʻokeʻo a he keʻokeʻo paha me kahi ʻōpala melemele. homogeneous. 1 ka pahu wai he 30 mg o octreotide. Nā mea kūʻai: kahi copolymer o DL-lactic a me ka glycolic acid - 850 mg, D-mannitol - 85 mg, carboxymethyl cellulose sodium salt - 30 mg, polysorbate-80 - 2 mg.

Haʻalele mannitol, maʻi houake 0.8% - 2 ml.

ʻO ka nui o ka hue wai o nā aniani o 10 ml. Kuhi i ka pahu kipa 1 ampoule o ka solvent, he syringe disable, 2 d / a me nā pono a me nā 2 wai kaona. Hoʻopili ʻia i kahi pahu pepa.

Nā ʻoihana ʻoihana ʻo ka lāʻau maʻi

ʻĀpana Pharmacotherapeutic

Somatostatin

ʻO ka hana lāʻau lapaʻau no ka lāʻau lapaʻau Octreotide Depot

ʻO ka Octreotide-depot he puka hana octreotide lōʻihi lōʻihi no ka hoʻokele intramuscular, e maopopo ai ka mālama ʻana i ka hoʻomau ʻana o ka paʻa o ka ʻona octreotide i loko o ke koko no nā wiki 4. ʻO Octreotide kahi hoʻomehana pathogenetic no nā maʻi kī e hōʻike ikaika ana i nā mea hoʻokomo somatostatin.

ʻO Octreotide kahi hana octapeptide synthetic o kahi derivative o ke kūlohelohe o ka somatostatin a he mau hopena o ka pharmacological like, akā he lōʻihi o ka lōʻihi o ka hana.

Ke hoʻomake nei ka lāʻau lāʻau i ka mea i hoʻonui ʻia e ka neʻe o ka hormone ulu (GH), me nā peptides a me ka serotonin i hana ʻia i ka ʻoihana endocrine gastroenteropancreatic.

I nā poʻe olakino olakino, ʻoctreotide, e like me somatostatin, ke kāohi nei i ka mea huna o GH i kumu ʻia e ka arginine, ka hana kino a me ka hypoglycemia insulin, nā mea huna o ka insulin, glucagon, gastrin a me nā peptides o ka ʻōnaehana endocrine gastroenteropancreatic, nā mea i ka ʻai ʻana i ka meaʻai, a me ka huna ʻana o ka arginine, ka hana ʻana i ka insulin nāʻaila i ka thyroliberin. ʻO ka hopena hoʻololi i ka mea huna o ka ulu ulu ʻana i octreotide, i ka ʻokoʻa ʻana i ka somatostatin, ua hōʻike ʻia i kahi nui loa ma mua o ka mea huna o ka insulin.ʻAʻole i alakaʻi ʻia ke octreotide e ka hanana me ke ʻano o ka hypersecretion o nā hormones e ka maikaʻi ʻona o ka pane.

I ka poʻe maʻi me ka acromegaly, hoʻolako ka hoʻomalu o Octreotide-depot i ka nui o nā hihia i ka hoʻomau mau nei o ka neʻe ʻana o GR a me ka normalization o ke kahe ʻana o ka like me ka mea ulu o ka insulin 1 / somatomedin C (IGF-1).

I ka hapa nui o nā poʻe maʻi me ka acromegaly, ʻo Octreotide Depot e hōʻemi nui loa i ka hōʻeha o nā hōʻailona e like me ke poʻo, ka laʻala, ka hōʻeha, ka ʻōpū, nā ʻeha o nā iwi a me nā hui, peripheral neuropathy. Hōʻike ʻia ʻo ka mālama ʻana me ka octreotide i nā mea maʻi me ka adenomas pituitary huna huna i alakaʻi i ka hōʻemi o ka nui o ka ʻōpū.

Me ka huna hakahaka endocrine o ka gastrointestinal tract a me ka pancreas, ka hoʻohana ʻana o Octreotide-depot hoʻolako mau i ka mālama mau ʻana i nā hōʻailona nui o kēia mau maʻi.

A 30 mg octreotide depot i kēlā me kēia he 4 wiki e hoʻohiolo i ka ulu ʻana i nā maʻi i nā mea maʻi me ka nūhou a me ka ʻike ʻole ʻole (metastatic) neuroendocrine tumuna o ka ʻili, ileum, makapō, piʻi i ke koleke, transverse colon a me nā nūnū ʻōpala, a metastases o kahi niko neuroendocrine. Ua hoʻonui nui ka lāʻau lapaʻau i ka manawa e holomua ai i kēia mahele o nā mea maʻi: ʻo ka manawa median i ka holomua ʻo 14.3 mau mahina e like me nā mahina 6 i ka hui plasebo. Ma hope o 6 mau mahina o ka mālama ʻana, ua nānā ʻia ʻo stabilization ma 66% o nā mea maʻi ma ka pūʻulu Octreotide-depot a me 37% o nā mea maʻi i ka hui plasebo. Loaʻa ka lāʻau lapaʻau i ka hoʻonui ʻana i ka manawa i ka holomua, ʻo ia no ka hūnā huna a ʻaʻole ʻole e hūnā ʻia i nā puku neuroendocrine.

I loko o nā maʻi carcinoid, hiki i ka hoʻohana ʻana o ka octreotide ke alakaʻi i ka hōʻemi o ka hōʻeha o nā hōʻailona o ka maʻi, ma mua loa, e like me "nā wela wela" a me nā maʻi puhaka. I nā hihia pinepine, ua hoʻopili ʻia ka holomua lapaʻau me ka hoʻohaʻahaʻa ʻana i ka plasma serotonin kukuna a me ka hoʻopiʻi ʻana o ka waila 5-hydroxyindoleacetic i loko o ka urine.

I loko o nā hua i hoʻākāka ʻia e ka hyperproduction o kahi peptide ʻōpū vasoactive (VIPoma), ka hoʻohana ʻana o octreotide i ka hapanui o nā maʻi e alakaʻi i kahi kaho o ka ʻōpū huna huna, ʻo ia ka mea o kēia ʻano, ka mea, e alakaʻi i ka hoʻomaikaʻi ʻana i ka maikaʻi o ke ola o ka mea maʻi. I ka manawa like, aia ke emi o ka hoʻohālikelike neʻe i loko o ke kaulike electrolyte, no ka laʻana, hypokalemia, kahi e ʻae ai iā ʻoe e hoʻopau i ka enteral a me nā palapala makua no ka wai me nā electrolytes. Wahi a tomography i hoʻohālikelike ʻia, i kekahi mau mea maʻi he lohi a hemo paha ka holo ʻana o ka ʻōpū, a me ka emi ʻana o kona nui, ʻo ia hoʻi nā metastases ate. Hoʻololi pinepine ʻia ka hoʻomaikaʻi ʻana i ka maʻi me ka hōʻemi (a hiki i nā waiwai maʻamau) i ka ʻike ʻana o ka peptide intestinal peptide (VIP) i loko o ka plasma.

Me nā glucagonomas, ʻo ka hoʻohana ʻana i ka octreotide i ka hapanui o nā hihia e alakaʻi i kahi ʻike nui ʻana i nā pihi migratory necratizing, ka mea e ʻano o kēia kūlana. ʻAʻohe o nā hopena koʻikoʻi o Octreotide i ka nui o ka maʻi mellitus, i mālama pinepine ʻia me ka glucagonomas, a maʻamau ʻaʻole ia e hōʻemi i ka pono o ka insulin a i ka lāʻau hypoglycemic oral. I nā poʻe maʻi me ka maʻi ʻaʻai, ʻo ka octreotide e hōʻemi i loko o ia mea, i hui pū ʻia e ka piʻi ʻana o ka nui o ke kino. Me ka hoʻohana ʻana o octreotide, kahi emi wikiwiki i ka neʻe o ka glucagon i loko o ka plasma e ʻike pinepine ʻia, akā naʻe, me ka hoʻōla lōʻihi, ʻaʻole mau kēia hopena. I ka manawa like, noho mau ka hoʻomaʻamaʻa like me ka lōʻihi no ka lōʻihi.

I loko o ka gastrinomas / Zollinger-Ellison syndrome, octreotide, i hoʻohana ʻia me ka monotherapy a i hui pū ʻia me histamine H 2 blockor blockers a me nā pale kiaʻi proton, hiki ke hōʻemi i ka hoʻokumu ʻana o ka waikila hydrochloric i loko o ka ʻōpū a alakaʻi i ka hoʻomaikaʻi ʻana i ka maʻi, e komo aie pili ana i ka huʻehaʻe. Hiki nō iā ia ke hōʻemi i ka ʻāʻī a me nā hōʻailona ʻē aʻe, ka pili pū me ka synthesis o nā peptides e ka ʻōpū, me nā Nā kuikahi. I kekahi mau hihia, aia ka emi o ka neʻe o ka gastrin i ka plasma.

I ka poʻe maʻi me ka insulin, ua hōʻemi ʻia ka octreotide i ka ʻaila o ka insulin immunoreactive i loko o ke koko. I nā mea maʻi me nā maʻi ʻoi aku, hiki i ka octreotide ke mālama i ka hoʻihoʻi a me ka mālama o ka normoglycemia i ka wā preoperative. I ka poʻe maʻi me ka maʻi o ka maʻi lōkahi, a me ka hoʻomaʻamaʻa ʻana o ka maʻi, hiki ke hoʻomāhuahua i ka mana o ka glycemic me ka hoʻokaʻawale mau ʻana i ka hoʻoliʻi ʻana o ka insulin i loko o ke koko.

I ka poʻe maʻi me nā manu hakahaka, ʻo ka hoʻokuʻu ʻana i ka hormone ulu ulu i waho (somatoliberinomas), e hōʻemi ana ka octreotide i ka nui o nā hōʻailona acromegaly. ʻO kēia, akene, ua pili pū me ka pani ʻana o ka mea huna o ka ulu ʻana o ka hormone hoʻoulu i kahi mea a me ka GH. I ka wā e hiki mai ana, hiki i ka hōʻemi ʻana i ka nui o ka hapia pituitary, i hoʻonui ʻia ma mua o ka mālama ʻana.

I nā mea maʻi me ka maʻi prostate hormone pale (HGRP), ka loko o nā pū neuroendocrine e hōʻike ana i ka hopena o ka hopena somatostatin e pili ana i ka octreotide (SS2 a me nā ʻano SS5), e hoʻoholo ana i ka hoʻowalewale o ka ʻōpala i ka octreotide. ʻO ka hoʻohana ʻana o ka Octreotide-Depot i hui pū me dexamethasone e kū'ē i ke kua ʻana o ka blockade androgen (ka lāʻau a i ʻole ka hōʻino ʻana) ma nā mea maʻi me HGRP e hoʻihoʻi i ka naʻau i ka therapy hormone a alakaʻi i ka emi ʻana o ka antigen spate (PSA) ma mua o 50% o nā maʻi.

I nā maʻi me HGRG me nā metastases o nā iwi, hui pū ʻia kēia mea e ka hopena me ka hopena analgesic i haʻi ʻia. Eia kekahi, i nā maʻi āpau i pane i ka hui hoʻohui pū me ka Octreotide Depot, ʻo ka maikaʻi o ke ola a me ka hoʻolaʻa median-ola ʻole maikaʻi i hoʻonui ʻia.

Lapaʻau lāʻau

ʻAʻole hāʻawi ʻia nā ʻikepili ma ka pharmacokinetics o ka lāʻau Octreotide-depot.

Acromegaly (i ka lilo ʻole o ka hopena kūpono mai ka hoʻomaʻemaʻe ʻana i ka maʻi, ka mālama ʻana i ka radiation a me ka mālama ʻana me ka agonists dopamine, i nā mea maʻi maʻi, a me ka poʻe maʻi e hōʻole nei i ka hana maʻi), nā hōʻaha i nā hōʻailona o nā hana o ka ʻoihana endocrine o ka gastroentero-pancreatic (kūloko carcinoid me ka noho ʻana o ka maʻi carcinoid, tumor. hōʻike ʻia e ka hua pākuʻi o kahi peptide ʻōpū o vasoactive - VIPs, glucagon, gastrinomas / Zollinger-Ellison syndrome), insulinomas, tumors kinipōpili e kahiʻai somatoliberin - somatoliberinomas, ka mea maʻi refractory i nā maʻi maʻi AIDS. ʻO ka pale ʻana i nā hoʻopiʻi ma hope o ka hōʻemi ʻana o ka pancreatic, hoʻopaʻa i ke koko a pale i ka hōʻea ʻana mai nā varicose veins o ka esophagus me ka cirrhosis (i hui pū me ka sclerotherapy endoscopic).

Nā Hoʻohui ka lāʻau lapaʻau

ʻO ka hypersensitivity i octreotide a i nā meaʻokoʻa'ē aʻe o ka lāʻau.

Me kamakaala Pono ka lāʻau e hoʻākāka no ka cholelithiasis, maʻi mellitus, i ka wā hāpai a me ka wā lactation.

Dodage regimen a me ke ʻano o ka noi Octreotide Depot

Pono ka lāʻohana o Octreotide-Depot e hana pū ʻia ma loko o ka intramuscularly hohonu (IM) wale nō, i loko o ka puʻu gluteus. Me nā ʻōkuhi helu hou, pono ke loli ka ʻaoʻao hema a ʻākau. Pono koke e hoʻomākaukau i ka hoʻopiʻi ʻana ma mua o ka paʻi ʻana I ka lā o ka inikua, hiki ke mālama ʻia i ke kīʻaha me ka lāʻau lapaʻau a me ka ampoule me ka pulima i ka mālama ʻana i ka lumi.

Ma ka hana ʻana o ka acromegaly i loko o nā mea maʻi no ka s / c hoʻokele o octreotide e hāʻawi pono i ka ʻoluʻolu o nā hōʻike o ka maʻi.ʻO ka dosis hoʻomaka ʻana o Octreotide Depot e 20 mg i kēlā me 4 wiki no 3 mahina. Hiki iā ʻoe ke hoʻomaka i ka mālama ʻana me Octreotide-Depot ma ka lā ma hope o ke kahie s / c hope o octreotide.I ka wā e hiki mai ana, e hoʻoponopono ʻia ka ʻomaʻi ʻana i nā mea pili i ka serum o GR a me IGF-1, a me nā hōʻailona maʻi. Inā ma hope o 3 mau malama o ka mālama ʻana ʻaʻole hiki ke hoʻokō i kahi hopena olakino a me ka hopena biochemical (ma ke ʻano he nui loa, inā e pili ana ke kāʻei o GR ma luna o 2.5 μg / L), hiki ke hoʻonui ʻia i kēia hāpana ma 30 mg lawelawe ʻia i kēlā me kēia 4 hebedoma.

I nā hihia i hala ma hope o 3 mau lā o ka mālama ʻana me Octreotide-Depot ma ke ʻano o 20 mg, kahi hōʻemi mau
serum GH kahe ma lalo o 1 μg / l, normalization o ke kaohi ʻana o ka IGF-1 a me ka nalo ʻana o nā huli hoʻohuli o ka acromegaly, hiki iā ʻoe ke hōʻemi i ka nui o ka lāʻau no ka lāʻau Octreotide-depot i 10 mg. Eia nō naʻe, ma kēia mau mea maʻi e loaʻa ana ka liʻiliʻi liʻiliʻi o Octreotide Depot, nā hana serum o GR a me IGF-1, a me nā hōʻailona o ka maʻi, pono e mālama pono ʻia.

ʻO ka poʻe maʻi e loaʻa ana i kahi kaomi paʻa o Octreotide-Depot e pono e hoʻāʻo ʻia i kēlā me kēia 6 mahina no ka nānā ʻana o GH a me IGF-1.

ʻO ka mea maʻi no ka mea e hoʻomaʻamaʻi ʻana i ka lāʻau lapaʻau a me nā maʻi radiation hiki ʻole ke kūleʻa i ka maʻi, a no ka poʻe maʻi e pono ai i ka hoʻolālā pōkole ma waena o nā papa o ka radiation radiation a hiki i ka hoʻomohala ʻana i kona hopena piha, ʻo ia ka mea e hana ʻia ai he papa hoʻokolokolo o ka mālama ʻana i nā s / c injections o octreotide i mea e loiloi ai i kāna ka hopena a me ka hoʻomanawanui nui, a ma hope wale nō o kēlā hoʻololi i ka hoʻohana ʻana i ka lāʻau no ka make ʻana ʻo Octreotide-depot e like me ke ʻano i luna aʻe.

I ka mālama ʻana i nā ʻaila o endocrine o ke akeʻai a me ka pancreas i loko o nā mea maʻi no ka ʻona s / c o ka octreotide ka hāʻawi o ka ʻono o ka nui o ka hōʻike o ka maʻi, ka ʻōlelo mua ʻana o ka lāʻau ʻo Octreotide-Depot he 20 mg i kēlā me 4 wiki. E hoʻomau ʻia ka hoʻokele sc o octreotide no 2 mau pule aʻe ma hope o ka hoʻokō mua ʻana i ka lāʻau ʻo Octreotide-Depot.

I ka poʻe maʻi ʻaʻole i loaʻa i mua o sperm octreotide, ke manaʻo ʻia e hoʻomaka ʻia ka mālama ʻana me ka hoʻōla ʻana o sct. Ma hope wale iho o kēia, ua kauoha ʻia ka lāʻau lapaʻau Octreotide-depot e like me ka hoʻolālā ma luna.

I ka hihia a ʻo ka therapy me Octreotide-Depot no 3 mau mahina e hāʻawi pono i ka mākaʻi o nā hōʻike lapaʻau a me nā hōʻailona olakino o nā maʻi, hiki ke hoʻemi i ka nui o ka huaʻāina o Octreotide-Depot i 10 mg,
i koho ʻia i kēlā me kēia 4 pule. I nā hihia i hala ma hope o 3 mau lā o ka mālama ʻana me Octreotide-Depot, ʻoiai wale nō ka hoʻonui ʻana i ka hoʻomaikaʻi ʻana, hiki ke hoʻonui ʻia ka nui i ka 30 mg i kēlā me 4 wiki. E kūʻē i ke kuʻuna o ka lapaʻau me Octreotide-Depot, i kekahi mau lā hiki ke hoʻonui ʻia i nā hōʻike kulana maʻi ʻano endocrine tumors o ka gastrointestinal tract a me ka pancreas. I kēia mau hihia, ua hāpai ʻia kahi lawelawe s / c o ka octreotide i kahi maʻa i hoʻohana ʻia ma mua o ka hoʻomaka ʻana o ka hoʻōla me ka Octreotide Depot. Hiki ke hana i kēia ma nā mahina 2 mua o ka mālama ʻana a hiki i ka ʻike ʻana o nā ʻekepili o octreotide i ka plasma.

ʻO nā mea huna a me ka huna ʻole ʻole (metastatic) ʻo nā ʻoiʻi neuroendocrine o ka ʻili o ka ʻili, ka ileum, makapō, ka piʻi ʻana o ka lāʻau, transvers colon a me ka appendix, a me ka metastasis o nā ʻalā neuroendocrine ʻole kahi lesion ma mua. ʻO ka paipai ʻia o Octreotide Depot he 30 mg i kēlā me kēia 4 pule. Pono e hoʻomau ka ʻomaʻomaʻo Octreotide-depot a hiki i nā hōʻailona o ka ulu ʻana i ka maʻi ʻaʻai.

I e mālama ʻia ana i ka maʻi prostate-pale kolohe ʻO ka dosis hoʻomaka ʻana o Octreotide Depot e 20 mg i kēlā me 4 wiki no 3 mahina. Ma hope aku, hoʻoponopono ʻia ka ʻae ʻana i ka noʻonoʻo ʻana i nā kumulāʻau o ka seru PSA serum, a me nā hōʻailona kino. Inā ma hope o 3 mau lā o ka mālama ʻana ʻaʻole hiki ke hoʻokō
pono ka lāʻau lapaʻau a me ka hopena biochemical (hoʻemi ʻia ka PSA), hiki ke hoʻonui ʻia ka nui o ka 30 mg e lawelawe ʻia i kēlā me kēia 4 pule.

Hoʻohui ʻia ka lāʻau lapaʻau me ka Octreotide Depot me ka dexamethasone, i kuhikuhi ʻia ma ke ʻano me ke ʻano e pili ana i kēia kumuhana: 4 mg i ka lā no ka mahina 1, a laila 2 mg i kēlā me kēia lā no 2 mau hebedoma, a laila 1 mg i kēlā me kēia lā.

ʻO ka mālama ʻana o Octreotide-depot a me dexamethasone o nā poʻe maʻi i hoʻomaʻamaʻa mua i ka lāʻau antiandrogen therapy i hoʻohui pū ʻia me ka hoʻohana ʻana o nā mea hoʻohālike o gonadotropin-hoʻokuʻu i ka hormone (GnRH). I kēia hihia, ʻo ka maʻi o ke kikowaena o GnRH (form depot) i lawe ʻia i ka manawa 1 ma ka 4 mau pule.

E hoʻāʻo ʻia nā mea maʻi e loaʻa ana iā Octreotide Depot i kēlā me kēia mahina no ka nānā ʻana o PSA.

I nā mea maʻi me ka renal impalired, hepatic, a me nā maʻi maʻi ʻAʻohe mea e pono e hoʻoponopono i ka regimen dosage o ka lālani Octreotide-depot.

No ka prophylaxis o kēlā me kēia pancreatitis postoperative ka lāʻau Octreotide-Depot i loko o kahi mahele o 10 a 20 mg o ka lawelawe ʻia i hoʻokahi manawa ma mua o 5 mau lā a ʻaʻole iʻoi aku ma mua o 10 mau lā ma mua o ka hana i manaʻo ʻia.

Na rula no ka hoomakaukau ana o ka hoopanee ana a me ka hooponopono ana i ka laau

Hoʻohana wale ʻia ka lāʻau lapaʻau i loko o ka aila. Ua hoʻomākaukau ʻia ka kāpae ʻia no ka ʻōlelo intramuscular me ka hoʻohana ʻana i ka pila i hāʻawi ʻia ma mua o ka hoʻokele ʻana. Pono e hoʻomākaukau ʻia ka lāʻau lapaʻau a mālama ʻia wale nō e nā limahana lapaʻau i aʻo ʻia.

Ma mua o ka ʻōlelo ʻana, pono ke kāpae ʻia nā ampoule me ka ipu hāpona a me ka hue me ka lāʻau lapaʻau mai loko o ka friji a lawe ʻia i ke kūmaha lumi (30-50 mau minuke e pono ai). Mālama i ka hue me ka lāʻau Octreotide-Depot kū pololei. Ka hoʻoweliweli ʻana i ka vial māmā, e hōʻoia i ka lalo o ka lyophilisate holoʻokoʻa ma lalo o ka vial.

E wehe i ka pale kuʻuna a hoʻopili i kahi nūpepa 1.2 mm x 50 mm i ka ʻāʻā maʻa e ʻohi i ka ʻai. E wehe i ka ampoule me ka hāmeʻa a waiho i loko o ka syringe nā kiko āpau o ka ampoule me ka uku pahu, hoʻonoho i ka syringe i kahi pāpaʻi o 2,0 ml. Hoʻokuʻu i ka pāpale palika mai ka panakī e loaʻa ai ka lyophilisate. Hoʻopilikia i nā mea pani kīʻaha o ke kīʻaha me kahi ʻōnaʻi waiʻona. Hoʻokomo i ka lāʻau pono i loko o ka pahu lyophilisate ma waena o ka pahu kaʻa kīpē a hoʻokomo pono i ka solvent ma ka ʻaoʻao o ka pā o ka vial me ka hoʻopā ʻole ʻana i nā mea o ke kīʻaha me ka pūpū.

Hoʻokuʻu i ka syringe mai i ke kīʻaha. Pono ka neʻe a kū i ka neʻe a hiki i ka hoʻomohala piha ʻana o ka puna me ka lyophilisate a me nā pakanika hoʻōki (no ka pili o 3-5 mau minuke). A laila, me ka ʻole o ka huli ʻana i ka hue maʻa, pono ʻoe e nānā no ka hele ʻana o ka lyophilisate maloʻo ma nā paia a i lalo o ka hue. Inā ʻike ʻia nā hopena maloʻo o ka lyophilisate, e waiho i ka vial a hiki i ka saturated piha.

Ma hope o kou ʻonikena ʻana i ka loaʻa ʻole o nā koena lyophilisate maloʻo, pono e hoʻopili pono ʻia nā kiko o ka vial i loko o nā neʻe a puni no 30-60 kekona a hiki i kahi hoʻokō homogeneous. ʻAʻole a kīwī paha i lohi paha i ka kīʻaha, no ka mea, he hopena kēia i ka pau ʻana o ka pīpī a me ka hoʻokipa ʻaʻole pono.

E hoʻopili koke i ka pūlima ma o ka mea pani kele i ka pahu. A laila ua hoʻohaʻahaʻa ʻia ka paukū ʻuma a, ma o ke kaomi ʻana i ke kīʻaha ma ke kihi o 45 degere, e huki koke i ka hoʻokuʻu ʻia ʻana i loko o ka syringe. Mai kiʻoki i ka hue inā paʻi. ʻO kahi liʻiliʻi o ka lāʻau lapaʻau e noho mau ma luna o nā paia a i lalo o kahi pākahi. ʻO ka hoʻohana ʻia no ke koena ma luna o nā paia a i lalo paha o ka hue.

Ma hope koke o ka hōʻiliʻili ʻana ʻana o ka puhoi, ke kahili ʻana i ka pono me ka poha ka ʻulaʻula me ka pāpala me ka pavilion kākele (0.8 x 40 mm), e akahele pono i ka syringe a wehe i ka lewa mai ka ʻihi.

ʻO ka hoʻokuʻuʻana i ka lāʻau no Octreotide-Depot e mālama koke ʻia ma hope o ka hoʻomākaukau. Hoʻopili ʻia kahi paʻa o ka lāʻau ʻo Octreotide-Depot me nā lāʻau lapaʻau ʻē aʻe i hoʻokahi syringe.

E hoʻohana i kahi swab i mea inu wai e hoʻomaʻemaʻe ai i ke kahua o ka injection. Hoʻokomo i ka pulika nui i loko o ka puʻu gluteus maximus, a laila hoʻihoʻi iki i ka syringe plunger i mea e hōʻoia ʻole ai kekahi pōʻino i ka moku.E hoʻolauna i ka hoʻolanʻi intramuscularly mālie me ke kaomi mau ʻana i ka plueer syringe.

Inā e hoʻokomo ia i kahi o ke koko, e pono ke hoʻololi ʻia ka wahi o ka injection. Ke keokeo nei i ka pono, e hoʻonoho me ka mea hou o ke anawaena o ka like.

Me nā ʻōkuhi helu hou, pono ke loli ka ʻaoʻao hema a ʻākau.

Nā hopena hopena

Nā kūloko kūloko: me ka mana o ka i / m o Octreotide-depot, hiki i ke ʻeha, hōʻemi pinepine ka nui a me nā ʻalā ma ka wahi o ka inikua (maʻa mau ke kala ʻana, pōkole).

Mai ka palaki kuʻekuʻe: anorexia, nausea, luaʻi, hōʻeha ka ʻōpū o ka ʻōpū, ke kuahiwi, ke ʻano ʻana i ke kino, hoʻomāhuʻi ʻia, pākiki, ʻaʻa. ʻOiai e hoʻonui nui ʻia ka momona o ka momona me nā feces, a hiki i kēia manawa ʻaʻohe ʻike e hiki ke hoʻomohala ka lōʻihi i ka mālama ʻana me ka octreotide i ka ulu ʻana o ka hemahema o kekahi mau mea kanu no ka malabsorption (malabsorption). Ma nā hanana lohi, hiki i nā mea like me ka hoʻokauʻeha o ka ʻōpū o ka ʻōpū e hiki ke hele: hiki i ka hoʻomohala holomua, ʻeha hōʻeha i ka wahi o ka epigastric, ka hoʻopaʻapaʻa ʻana o ka pā o ka ʻōpū. ʻO ka hoʻohana lōʻihi ʻana o Octreotide Depot hiki ke alakaʻi i ka hoʻokumu ʻana o nā gallstones.

Mai ka pancreas: nā hihia i loaʻa ʻole o ka pancreatitis hoʻonā i kūkulu ʻia i nā hola mua a i ʻole mau lā i hoʻohana ʻia ai ka octreotide. Me ka hoʻohana mau ʻana, aia nā hihia o ka pancreatitis e pili ana me ka cholelithiasis.

Mai ka ate: Aia nā hōʻike ʻokoʻa i ka hoʻomohala ʻana i ka hana o ka puʻuwai lēwa (hepatitis akue ʻole me ka cholestasis me ka normalization o transaminases ma hope o ke hoʻopau ʻana o ka octreotide), ka hoʻomohala ʻana i ka holomua o ka hyperbilirubinemia, i hui pū ʻia e ka piʻi ʻana o ka ALP, GGT a, me ka mea haʻahaʻa, ʻokoʻa nā transaminases.

Mai ka ʻaoʻao o ka metabolism: Ma ka hopena o ka Octreotide Depot ka hopena nui ma ka hoʻokumu ʻana o GH, glucagon a me insulin, hiki iā ia ke pili i ka metabolism glucose. Hiki i ka hoʻololi ʻana i ka hoʻohaʻahaʻa glucose i hope o ka ʻai ʻana. Me ka hoʻohana mau ʻana o ka haʻina o Octreotide i kekahi mau hihia, e ulu mau ka hyperglycemia hoʻomau. Ua nānā ʻia ka hypoglycemia.

Nā ʻili: i nā hanana i loaʻa i ka hanana, nā lūlū o ka lauoho ma hope o ka hoʻokō ʻana o ka octreotide, ka hōʻeha ʻana o ka bradycardia, tachycardia, ka pōkole o ka hanu, ʻāwili ka ʻili, anaphylaxis i hōʻike ʻia. Aia nā hōʻike kūʻokoʻa ma ka hoʻolālā ʻana o ka hopena hypersensitivity.

ʻŌpū a me ka lactation

ʻAʻoheʻike i loaʻa me Octreotide Depot i ka wā hapai a i ka wā o nā umauma.

No laila, i ka wā hāpai, pono ke hoʻomaopopo ʻia ka lāʻau lapaʻau inā inā ʻo ka pono o ka makuahine i ʻoi aku ka nui o ka maʻi i ka ʻōpū.

ʻAʻole kūkākūkā ʻia ka wā lohi e hoʻohana i ka lāʻau i ka wā lactation.

Ke noi no ka hana ʻōlima hemahema i nā mea maʻi me ka hana o ka puʻuwai hemahema, ʻaʻohe pono e hoʻoponopono i ka hoʻoponopono ʻia o ka ʻāina ʻo Octreotide-Depot.

Hoʻohana i nā mea maʻi maʻi

I nā poʻe maʻi ʻelemakule, ʻaʻohe mea e pono e hoʻoponopono i ka regimen dosis no Octreotide Depot.

Nā ʻōlelo kikoʻī kūikawā no ke komo ʻana Octreotide Depot

Me nā tumors pituitary, pono pono ka nānā ʻana i nā poʻe maʻi ma muli o ka hiki ke hoʻonui ʻia i ka nui o nā hakahaka me ka hoʻomohala ʻana o ka liʻiliʻi o nā māla ʻike. I kēia mau hihia, pono ʻoe e noʻonoʻo i ka pono no nā ʻano lāʻau ʻē aʻe. I ka loaʻa ʻana o nā hōʻeha endocrine gastroentero-pancreatic i nā hanana loaʻa, hiki i kahi hōʻemi ke hōʻailona i nā hōʻailona. I ka poʻe maʻi me ka insulinomas i ka wā mālama, hiki ke hoʻonui ʻia i loko o ka nui a me ka lōʻihi o ka hypoglycemia. ʻO ka hōʻeha o nā hopena ʻaoʻao mai ka gastrointestinal tract e hoʻohaʻahaʻa me ka hoʻopukaʻana i ka lāʻau lapaʻau ma waena o nā meaʻai a i ka wā hiamoe paha.Me ka lōʻihi o ka hoʻōla (acromegaly), ma mua a i ka wā o ka mālama ʻana (kēlā me kēia mahina 6-12) - ka loaʻa ʻana o ka maʻi maʻi.

ʻO nā pōhaku i loko o ka gallbladder, inā naʻe, ke ʻike nei lākou, ka mea maʻamau asymptomatic. I mua o nā hōʻailona o ka lāʻau lapaʻau, hōʻike ʻia ka hoʻomaʻamaʻa ʻana a me ke ʻano mālama. Hōʻalo i nā inikini he nui ma ka wahi like i ka manawa pōkole. Ma mua o ka hoʻokele ʻana, hoʻomehana i ka hoʻonā i ka mahana o ka lumi. Hoʻohana i ka wā hāpai a me ka lactation wale nō ma nā hōʻike mau loa. Hiki ke hōʻemi ʻia nā hōʻemi i loko o ka hoʻoliʻiliʻi o ke koko e ka hoʻokele pinepine ʻana i nā papa haʻahaʻa. I ka wā o ka mālama ʻana, pono ka nānā ʻana i ke kūpaʻa o ka glucose o ke koko, ka mea pono i nā mea maʻi me ka hoʻokahe ʻana mai nā varicose veins o ka esophagus me cirrhosis o ka ate - he nui ka hoʻonui ʻana o ka hoʻomohala ʻana i ka hyperglycemia.

Ke keu

I kēia manawa, ʻaʻole i hōʻike ʻia nā hihia o ka hala o Octreotide-Depot.

Nā pilina pili me nā lāʻau lapaʻau ʻē aʻe

Hoʻololi ʻo Octreotide i ka hoʻihoʻi ʻana o ka cyclosporin mai ka ʻōpū a waiho ʻana ma kahi o ka hoʻopili ʻana o cimetidine.

Me ka hoʻohana like ʻana o octreotide a me bromocriptine, hoʻonui i ka bioavailability o ka hope.

Aia kahi mana e pili ana i ka mea hiki i nā analogat somatostatin ke hōʻemi i ka hoʻokaʻawale i ka metabolic o nā mea i hoʻokaʻawale e nā isoenzymes o ka cytochrome P450, hiki i ka hopena o ke kāohi ʻana o GR. I ka hiki ʻole ke hoʻokaʻawale i nā hopena like o octreotide, nā lāʻau lapaʻau e hoʻoliʻohui e nā isoenzymes o ka ʻōnaehana cytochrome P450 a loaʻa iā lākou kahi ākea terapeutic kūʻokoʻa (quinidine a me terfenadine) e kuhikuhi me ka akahele.

Hoʻohui Kūʻai Kūʻai

Ke kūleʻa aku nei ka lāʻau lapaʻau.

Nā kuleana a me nā kūlana e waiho ai

Pono ke mālama i ka lāʻau ma kahi maloʻo a pouli hoʻi, i waho o nā keiki i kahi mahana o 2 ° a 8 ° C. ʻO 3 mau makahiki kahi ola i nā pale.

ʻO ka hoʻohana ʻana i ka lāʻau lapaʻau Oktreotid-depot wale nō e like me ka mea i kuhikuhi ʻia e ke kauka, ua hāʻawi ʻia nā ʻōkuhi no ke kuhikuhi!

E hoʻokuʻu i ke ʻano

Loaʻa ka lāʻau lapaʻau i ke ala o ka hopena no ka hoʻonāka ʻia, waiho ʻia i loko o 1 ml ampoules a i ʻole 5 mau pahu wulu.

Octreotide Depot a ʻO Octreotide Long loaʻa i ke ʻano o ka pauna lyophilized i hoʻopaʻa ʻia a i ʻole ka nui i loko o ke ʻano o kahi papa kukui ʻoniʻoni o nā ʻano like ʻole. Eia kekahi, kahi paʻa i ka hoʻohuihui manuahi ʻole a me ka hoʻihoʻi hou ʻana, ʻo ia kahi hoʻopiʻi homogeneous kahi pale kukui, e hoʻopili ʻia.

Eia kekahi, hiki ke hāmama ʻia kēia mau ʻano lāʻau lapaʻau i ke ʻano o ka lyophilisate no ka hoʻomākaukau ʻana i kahi hoʻopanee i manaʻo ʻia no ka hoʻoponopono intramuscular me ka hana lōʻihi o ka 0,01-0.03 g o ka mea hoʻoikaika i nā pahu wai aniani. Eia kekahi, aia ka pahu i ka 2 ml o kahi ampoule me kahi pae pākele, kahi syringe disposable, jarile ka wai a me ka ʻawaʻawa. ʻO kekahi hoʻonohonoho no ka mea hoʻokahi wahahee.

Pharmacodynamics a me ka pharmacokinetics

ʻO kēia lāʻau lapaʻau kahi mea hoʻohālike synthetic. somatostatini nā hopena lapaʻau like like, akā lōʻihi ka lōʻihi.

Hoʻohana ʻia ka lāʻau mālama Octreotide i ka wā e pono ai ke hoʻopaʻa i ka mea huna o ka ulu ulu ʻana, hoʻonui pathologically a i ʻole ʻia e ka ʻĀlani, insulin hypoglycemia a i ʻole ka hoʻoikaika kino. Hoʻomaʻemau ka hopena poloka o ka insulin, gastrin, glucagon a serotinin, hiki ke hoʻonui ʻia me nā pathologically a i ʻole ʻia e ka ʻahaʻaina. Ua hoʻomaopopo ʻia ka ʻona ʻōlelo huna insulina nāonaonae hoʻālaʻĀlanihoʻemi i ka huni pilawopomāe ʻia e kāu piliona.

Ke hoʻohana nei i ka lāʻau lapaʻau ma mua a i ka wā o ka hōʻemi pancreatic hiki ke hōʻemi i ka loaʻa ʻana o nā ʻōpiopio postoperative ʻano, no ka laʻana:fistula pancreatic, sepsis, abscesses, pancreatitis postoperative aʻai.

ʻO ka lapaʻau o ke koko mai nā varicose veins i ka gastrointestinal tract i loko o nā poʻe maʻi e loaʻa ana i ka cirrhosis o ka ate i hui pū ʻia me kahi hana maʻi kūikawā - sclerosing and hemostatic, kōkua i ka hoʻomaikaʻi maikaʻi ʻana i ka pale ʻana a pale hou i ke kahe mau ʻana.

I loko o ke kino ke hele a wikiwiki a piha i ka waiwai hoʻoikaika. I kēia hihia, ʻo ka nui o ka ʻike ʻana o Octreotide i loko o ke kaila koko ua hōʻea ma hope o 30 mau minuke. Hoʻopili ka māhele i nā protein o ka plasma e 65%, akā ʻo kāna pilina me nā mea i hana ʻia o ke koko he mea kīnā ʻole loa. ʻO ka hoʻoneʻe ʻana o ka lāʻau lapaʻau e loaʻa mai i kekahi mau hanana ma o ka ʻōpū a me ke kōkua o nā keiki.

Nā hōʻailona no ka hoʻohana ʻana

ʻO nā lāʻau lapaʻau-ʻenemi hākoti i kuhikuhi ʻia no:

• acromegalyinā hoʻokomo ʻia ka maikaʻi ʻoleagonists dopaminea ʻoiai ke hiki ʻole ke hoʻokō ʻia a me ka hōʻoki ʻana i ka maʻi radiation.
• mau huaʻaloko endocrine ʻōnaehana gastroenteropancatic,
• glucagonomas, gastrinomas,
• insulomas, paulamala93
• paiena nā ninia i nā maʻi me ka maʻi AIDS
• hana ʻo ka pancreatic, me ka pale ʻana o nā hoʻopiʻi,
• kahe koko, ka pale ʻana o ka hoʻihoʻi ʻana i nā hihia o varicose veins o ka esophagus me cirrhosis o ka ate a pēlā aku.

Nā Hoʻohui

ʻO nā contraindication nui i ka hoʻohana ʻana i kēia lāʻau lapaʻau haaheo.

Pono e mālama ʻia i ka wā e mālama ai i nā maʻi maʻi. cholelithiasis,maʻi maʻi,ma lactation a hapai.

Nā hopena hopena

Ke mālama nei me Octreotide, hiki i nā pilikia ke hana i ke hana o ka kūwaho huehue hiki ke hele mai i loko o ke ʻano o ka: luaʻi, nilo, anorexiaʻeha ʻōpūmetheorrhea, ʻōpū o ka ʻawaʻawa, hepatitis akamai me ke kū ʻole o cholestasis, ka hana i hoʻonui ʻia o nā transaminases hepatic, hyperbilirubinemia, maʻi pancreatitis maʻa me nā mea ʻē aʻe.

E ulu pū kekahialopecia a nā hopena kūlohelohe. ^ E Ha yM. ʻAʻole i hoʻokaʻawale ʻia nā hōʻike kūloko: ʻeha, ʻeha, ʻāʻī, ʻulaʻula a i ʻole ka māla ʻana. ^ E Ha yM. Hoʻohana pinepine ʻia ka hoʻohana ʻana i ka wā lōʻihi me ka hoʻokumu ʻana o nā gallstones, hoʻemi i ka hoʻomanawanui i ka glucose, a hoʻomau hyperglycemia, hypoglycemia.

ʻO Octreotide, nā ʻōlelo e hoʻohana ai (ʻo ke ʻano a me ke ʻano)

ʻO ka lāʻau lapaʻau ʻO Octreotide i manaʻo ʻia no intravenous, intramuscular a i ʻole ʻĀpana hoʻokolohua. ^ E Ha yM. Hoʻonohonoho ʻia ka ʻākā hoʻokahi, me ka noʻonoʻo ʻana i ke ʻano o ka maʻi a me nā ʻano o ka mea maʻi. No ka laʻana, acromegaly a me nā pihi o ka ʻōnaehana o ka gastroenteropancreatic e koi ai i ka hoʻokele subcutaneous i kēlā me kēia lā o 1-2 mau manawa ma 50-100 mcg. Ke lawe nei i ka pale ʻana o nā hoʻopiʻi ma muli o ka hana ma ka pancreas e pili ana i ka hoʻoponopono subcutaneous o ka pākaʻi mua i hoʻokahi hola ma mua o ka laparotomy, a laila e lawelawe ʻia i kēlā me kēia lā 3 mau 100 g i kēlā me kēia pule. I ka manawa e koi ʻia e pani ai i ke kahe mai nā varicose veins o ka gastrointestinal tract, ka hoʻomau ʻia ʻana o ka infravenous infusions o 25 μg / h ke lawelawe ʻia ma kahi o 5 mau lā.

Nā ʻōkuhi no ka hoʻohana Octreotide Depot a Octreotide Long FS hōʻike e manaʻo nei no ka wii hohonu a intramuscular i ka huamo gluteal. Ke hoʻohālikelike nei ka hoʻokele subcutaneous o Octreotide i nā mea maʻi e hoʻomau i ka hōʻike o ka maʻi, ua kuhikuhi ʻia ka pualua mua o Depo a me Long ma 20 mg i kēlā me 4 wiki no 3 mau mahina. A laila hoʻoponopono ʻia ka dosage ma muli o nā mākau ola o nā maʻi a me nā hōʻailona koʻikoʻi.

Inā ʻaʻole i loaʻa i nā mea maʻi mua ka Octreotide subcutaneously, a laila hoʻomaka ka lāʻau me kēia aila a me nā ʻano no nā wiki 2. E nānā kēia ʻano i ka hana a me ke ahonui, a laila hiki iā ʻoe ke hana i ka mālama ʻana me Octreotide-Depot a i ʻole Long.

Ke keu

Inā i loaʻa ʻole kahi overdose o Octreotide a i ʻole Octreotide-Long, hiki i kēia mau mea: hōʻemi pōkole i ka piʻi ʻana o ka puʻuwai, ʻeha ka ʻōpū ʻano kikoʻī nininika maka o ka maka, nā ninia. ^ E Ha yM. I kēia hihia, e hoʻomaʻamaʻa ʻia ke ʻano hōʻailona maʻi.

ʻAʻole hōʻike ʻia nā hihia o kahi overdose o Octreotide-Depot i loko o ka hoʻomaʻamaʻa loea.

Hoʻohui

Hoʻohana pinepine ʻia o ka lāʻau lapaʻau me Cyclosporinehoʻohaʻahaʻa i kona pae i ka serum, e hoʻolohi ana i ka hoʻopili ʻanacimetidine a me nā mea pono ʻoluʻolu mai ka huina o ka huina. Inā kuhikuhi ʻia ka octreotide meinsulinwaha nā lāʻau maʻi hypoglycemic, mau pōʻai beta, BKK a o hoʻoiho, he mea pono ia e hoʻoponopono i kā lākou papaʻaʻi. Hoʻohana me Bromocriptine hoʻonui paha kona bioavailability.

Ua loaʻa i kēia lāʻau lapaʻau ka hōʻemi ʻana i ka pauku metabolic o nā mea i hoʻohālikelike ʻia e nā enzyme cytochrome P450 i kumu no ka pani ʻana o ka ulu ulu ʻana. No laila, i ke koho ʻana i nā lāʻau lapaʻau, pono e mālama.

Nā kikowaena o Octreotide

I loko o ka pharmacology, ua loaʻa nā helu like ʻole o Octreotide, ʻo ia ka mea nui Sandostatin.

Loaʻa kahi hopena like ia:Somatostatin, Diferelin a Sermorelin.

E like me kāu e ʻike ai, hiki i ka waiʻona ke pale i ka synthesis honaNo laila, ua hoʻohana nui ʻia kona hoʻohana me kekahi ʻano o Octreotide.

Hōʻikeʻike e pili ana iā Octreotide

Pono e hoʻomaopopo ʻia he mau kūkākūkā pūnaewele e pili ana i ka hoʻohana ʻana i kēia lāʻau lapaʻau a me kona pono. ʻO ka maʻamau, nīnau nā mea hoʻohana i nā nīnau i nā poʻe loea i makemake lākou i ka pehea e hoʻokō pono ai i ka hōʻola o kahi maʻi maʻi.

Eia nō naʻe, ma ka hana pilikino, hoʻohana nui ke ʻano Depot. I ka manawa like, nā loiloi ma Octreotide Depot hōʻike i ia mea no ka lōkohu, me nā wīwī a me ke ʻano o kēiaʻano ʻino. ʻO kaʻoiaʻiʻo, ua kau wale ʻia kēia mea hoʻōla ma ka loea a ʻo ka mea i manaʻo ʻia e mālama ʻia ka lāʻau no ka liʻiliʻi ma ka hebedoma.

Pākuʻi helu

ʻO ka Lyophilisate no ka hoʻomākaukau no ka hoʻomaha no ka hoʻokō intramuscular o ka hana lōʻihi o ka 10.0 mg, 20.0 mg a i ka 30.0 mg piha me ka hoʻoneʻeneʻe o 2 ml (Mannitol, hoʻonāuki ainake 0.8% 2 ml)

Hoʻokomo kahi pahu

mea waiwai - octreotide 10.0 mg, 20.0 mg, 30.0 mg,

nā mea hoʻowalewale: copolymer o DL-lactic a me ka glycolic acid, D-Mannitol, carboxymethyl cellulose sodium salt, polysorbate-80.

Haʻalele D-Mannitol, wai no ka ʻai maʻi.

ʻO ka ʻāpana Lyophilized a i ʻole porous, i hoʻopaʻa ʻia i kahi papa papa, ka nui o ke keʻokeʻo a i keʻokeʻo paha me kahi kapa melemele nāwaliwali.

Haʻalele hāmole kala kala ʻole

Hoʻopaʻa hou ʻia Me ka hoʻohui o ka maʻa a me ka hoʻonaninani, kahi hoʻopiʻi homogeneous i kahi keʻokeʻo keʻokeʻo a keʻokeʻo paha me kahi kūlana melemele hina polū. ʻO ka hoʻopiʻi ʻana i hoʻopiʻi ʻia ʻaʻole e lilo i mea e liʻiliʻi loa ma ka 5 mau minuke. Ke kū, ke kū nei ka lohi, akā hoʻokuʻi hou ʻia me ka haʻalulu. E hele paʻa ka hoʻokuʻu ʻia ʻana o ka pakanā ʻana i ka pū waikā No. 0840.

ʻO nā waiwai Pharmacological

Lapaʻau lāʻau

Me ka hoʻokele intramuscular, hoʻopili piha ʻia ka octreotide.

Hoʻopili ke kuhi therapeutic i loko o ke koko ma hope o 30 mau minuke.

ʻO ka pilina Protote e pili ana i ka 65%. Hoʻololi loa ka hoʻopaʻa ʻana o ka octreotide i nā sela koko. ʻO ka nui o ka hoʻoilina he 0.27 l / kg. Hoʻomili ka Octreotide i nā leʻa.

ʻO ka huina piha he 160 ml / min. T1 / 2 he 100 min. Ma kahi o 32% i ulana like ʻole e hoʻopili ʻia e nā keiki. I nā poʻe maʻi ʻelemakule, hōʻemi ka hoʻomaʻamaʻa ʻana, a me ka hoʻonui o T1 / 2. Ma kahi hōʻahewa koʻikoʻi, hoʻokaʻawale ke kelepona.

Phuhuleae

ʻO ka Octreotide Depot kahi syntical octapeptide kahi derivative o ka hormone kūlohelohe somatostatin a he mau hopena lapaʻau like like, akā naʻe he lōʻihi lōʻihi o ka hana. Ke hoʻomake nei ka lāʻau lāʻau i ka mea i hoʻonui ʻia e ka holomua o ka hormone holomua (GH), a me nā peptides a me ka serotonin i hana ʻia i ka ʻoihana endocrine gastro-entero-pancreatic.

I nā mea kāmua ʻo ka hoʻohana ʻana o Octreotide e alakaʻi i ka emi ʻana o ka hōʻeha o nā hōʻailona e like me ka sensations o ka flushing a me ka maʻiʻeha, a i nā nui he hui pū ʻia me ka hoʻokaʻawale ʻana o ka serotonin i loko o ka plasma a me ka hoʻōho ʻana o ka 5-hydroxyindoleacetic acid i loko o ka urine.

I ʻākala i hōʻike ʻia e ka momona o ka peptide ʻōpū o ka vasoactive (VIPs), ʻo ka hoʻohana ʻana iā Octreotide e alakaʻi i ka emi ʻana o ka maʻi huna secretory kino. I ka manawa like, loaʻa kahi hōʻemi i ke kūlea electrolyte concomitant. I kekahi mau mea maʻi, aia ka lohi a wīwī paha i ka holomua o ka hoʻoulu a hiki i ka emi ʻana o kona nui, ʻo ia hoʻi nā metastases ate. Hoʻololi pinepine ʻia ka hoʻomaikaʻi ʻana i ka maʻi me ka hōʻemi (a hiki i nā waiwai maʻamau) i ka ʻike ʻana o ka peptide intestinal peptide (VIP) i loko o ka plasma.

I nā glucagonomas ka hoʻohana ʻana o Octreotide-depot i ka hapanui o nā hihia e alakaʻi i kahi nui ʻana i ka pate migratory necratizing. ʻAʻohe hopena koʻikoʻi o Octreotide-depot i ka nui o ka hoʻonaninani o ka maʻi mellitus, i ʻike pinepine ʻia e ka glucagonomas, a maʻamau ʻaʻole e hōʻemi i ka pono o ka insulin a i ka lāʻau hypoglycemic oral. I nā maʻi me ka maʻi maʻi, ʻo Octreotide e hōʻemi i loko o ia mea, i hui pū ʻia e ka hoʻonui ʻana o ka paona kino. Me ka hoʻohana ʻana o Octreotide, kahi emi wikiwiki i ka neʻe o ka glucagon i loko o ka plasma e ʻike pinepine ʻia, akā naʻe, me ka mālama lōʻihi, ʻaʻole mau kēia hopena. I ka manawa like, noho mau ka hoʻomaʻamaʻa like me ka lōʻihi no ka lōʻihi.

I ʻunui gastrinomas / Zollinger-Ellison ʻO ka depre o Octreotide, hoʻohana ʻia ma monotherapy a i hui pū paha me nā blockers H2-receptor, hiki ke hōʻemi i ka hoʻoneʻe ʻana i ka waikawa i loko o ka ʻōpū a alakaʻi i ka holomua lapaʻau, me ka pili me ka ʻeha. ʻO ka hōʻemi o nā hōʻailona'ē aʻe, me ke kau ʻana, e hoʻoemi ʻia hoʻi. I kekahi mau hihia, aia ka emi o ka neʻe o ka gastrin i ka plasma.

I nā maʻi me i nā wīwī ʻO ka depre o Octreotide e hōʻemi i ka pae o ka insulin immunoreactive i loko o ke koko (hiki i kēia hopena ke wā pōkole loa - ma kahi o 2 mau hola). I ka poʻe maʻi me ka maʻi ʻeha, hiki i ka Octreotide Depot ke mālama i ka hoʻihoʻi a me ka mālama o ka normoglycemia i ka wā preoperative. I ka poʻe maʻi me ka maʻi o ka maʻi lōkahi, a me ka hoʻomaʻamaʻa ʻana o ke ʻano o ka maʻi, hiki ke hoʻomaikaʻi ʻia ka mana o ka glycemic me ka pākuʻi ʻana o ka nui o nā pae o ka nui o ka insulin.

I ka maʻi hoʻomehana i loko o nā mea maʻi me ka immunodeficiency syndrome (AIDS) lilo ka hoʻohana o Octreotide e hoʻokō a hoʻoli ʻole paha i ka hoʻonaninani ma kahi o ka 1/3 o nā poʻe maʻi e hōʻeha nei i ka maʻi laʻa, ʻaʻole i kaohi ʻia e ka lawa antimicrobial a me / a me nā lāʻau antidiarrheal.

I ka hoʻomanawanui i hana ʻia e ka hoʻomaʻamaʻa pancreatic, ka hoʻohana ʻana o Octreotide i ka manawa a ma hope o ka hōʻoki ʻana ke hōʻemi nei i nā hanana hou o ka hoʻopiʻi postoperative (no ka laʻana, ka pancistatic fistula, abscesses, sepsis, postoperative acute pancreatitis).

I huki ʻana mai nā maʻi varicose o ka esophagus a me nā ʻōpū i loko o nā mea maʻi me ka cirrhosis ka hana ʻana o Octreotide-Depot e hui pū me ka mālama kūikawā (no ka laʻana, ka sclerotherapy) alakaʻi i kahi ʻoi aku ka maikaʻi o ke kahe a me ka hoʻoliʻi hou ʻana i ke kahe, a me ka hoʻokaʻawale ʻana i ka nui o nā kaila a me kahi hoʻomaikaʻi i ke ola 5-lā. ʻO ka lāʻau lapaʻau e hōʻemi i ke kahe koko o ke kino ma o ke kāohi ʻana i nā hormones vasoactive e like me VIP a me glucagon.

ʻLoe a me ke kākele

Pono ka hoʻokele ʻana o Octreotide depot e hoʻopili hohonu wale i ka intramuscularly (IM) i loko o ka gluteus maximus. Me nā ʻōkuhi helu hou, pono ke loli ka ʻaoʻao hema a ʻākau. Pono koke e hoʻomākaukau i ka hoʻopiʻi ʻana ma mua o ka paʻi ʻana I ka lā o ka inikua, hiki ke mālama ʻia i ke kīʻaha me ka lāʻau lapaʻau a me ka ampoule me ka pulima i ka mālama ʻana i ka lumi.

I ka mālamaʻana i nā hana endocrine o ka gastrointestinal tract a me ka pancreas

I nā mea maʻi no ka mana s / c hoʻomalu o Octreotide e hāʻawi pono i ka mākeke kūpono o nā hōʻike o ka maʻi, ua kuhikuhi ʻia ka pualikua mua o Octreotide Depot he 20 mg i kēlā me 4 wiki. E hoʻomau ʻia ka hoʻokele sc o Octreotide no 2 mau pule aʻe ma hope o ka hoʻokele mua o Octreotide Depot.

I ka poʻe maʻi i loaʻa ʻole ma mua o Octreotide s / c, ua manaʻo ʻia e hoʻomaka i ka mālama ʻana me ka s / c hoʻokele ʻo Octreotide i kahi maʻa o 0.1 mg 3 mau manawa / lā no kahi manawa pōkole (ma kahi o 2 wiki) e nānā i kona hana a me ka hoʻomanawanui maʻamau . ^ E Ha yM. Ma hope wale nō o kēia ma mua, ua kuhikuhi ʻia ʻo Octreotide Depot e like me ka hoʻolālā ma luna.

I ka hihia i ka wā o ka terapi me Octreotide-Depot no 3 mau mahina e hāʻawi pono i ka ʻona o nā hōʻike lapaʻau a me nā hōʻailona o ka maʻi o ka maʻi, e hiki ke hoʻemi i ka nui o ka lā o Octreotide-Depot e 10 mg i kuhikuhi ʻia i kēlā me kēia 4 hebedoma. I nā hihia i hala ma hope o 3 mau lā o ka mālama ʻana me Octreotide-depot i loaʻa wale i ka hoʻomaikaʻi ʻana i kahi ʻāpana wale nō, hiki ke hoʻonui ʻia ka nui i ka 30 mg i kēlā me 4 wiki. E kū'ē i ka maikaʻi o ka mālamaʻana me Octreotide-depot, hiki i kekahi mau lā ke hoʻonui i nā ʻōlinike maʻi i hōʻike ʻia o nā ʻōpū o endocrine o ka gastrointestinal tract a me ka pancreas. I kēia mau hihia, ua hōʻike ʻia kahi kulekele s / c o Octreotide i kahi maʻa i hoʻohana ʻia ma mua o ka hoʻomaka ʻana o ka mālama ʻana me Octreotide-depot. Hiki i kēia ke hana i ka 2 mau mahina o ka mālama mua a hiki i ka hoʻokō ʻana o nā ʻohioma o nā octreotide i ka plasma.

I ka mālama ʻana i ka maʻi prostate-pale cancer ʻO ka dosis hoʻomaka ʻana o Octreotide Depot e 20 mg i kēlā me 4 wiki no 3 mahina. Ma hope aku, hoʻoponopono ʻia ka ʻae ʻana i ka noʻonoʻo ʻana i nā kumulāʻau o ka seru PSA serum, a me nā hōʻailona kino. Inā ma hope o 3 mau malama o ka mālama ʻana ʻaʻole hiki ke hoʻokō i kahi kūpono ʻoi a me ka hopena biochemical (hoʻemi i ka PSA), hiki ke hoʻonui ʻia i kēia momona a 30 mg lawelawe ʻia i kēlā me kēia 4 hebedoma.

Hoʻohui ʻia ka lāʻau lapaʻau ʻo Octreotide-depot me ka hoʻohana ʻana o dexamethasone, i kuhikuhi ʻia i ka waha me ka papa e like me kēia: 4 mg i ka lā no ka 1 mahina, a laila 2 mg i ka lā no 2 mau pule, a laila 1 mg i ka lā (e mālama ʻia ana).

ʻO ka hoʻōla ʻana me ka octreotide-depot a me dexamethasone i nā poʻe maʻi i hoʻomaʻamaʻa mua i ka lāʻau antiandrogen therapy i hoʻohui pū ʻia me ka hoʻohana ʻana o ka analogue o gonadotropin-hoʻokuʻu i ka hormone (GnRH). I kēia hihia, ʻo ka maʻi o ke kikowaena o GnRH (form depot) i lawe ʻia i ka manawa 1 ma ka 4 mau pule.

E hoʻāʻo ʻia nā mea maʻi e loaʻa ana iā Octreotide Depot i kēlā me kēia mahina no ka nānā ʻana o PSA.

I nā mea maʻi me ka renal impaired, hepatic, a me nā maʻi maʻi maʻi, ʻaʻohe mea pono e hoʻoponopono i ke kākā ʻai o ka hopena o Octreotide Depot.

No ka paleʻana o ka pancreatitis postoperative ʻoi aʻe

ʻO ka lāʻau Octreotide-Depot i kahi maʻa o 10 a i ʻole 20 mg e lawelawe ʻia i hoʻokahi manawa ma mua o 5 mau lā a ʻaʻole iʻoi aku ma mua o 10 mau lā ma mua o ka kolohe ʻana i manaʻo ʻia.

Na rula no ka hoomakaukau ana o ka hoopanee ana a me ka hooponopono ana i ka laau

Hoʻohana wale ʻia ka lāʻau lapaʻau i loko o ka intramuscularly.

Ua hoʻomākaukau ʻia ka kāpae ʻia no ka ʻōlelo intramuscular me ka hoʻohana ʻana i ka pila i hāʻawi ʻia ma mua o ka hoʻokele ʻana.

Pono e hoʻomākaukau ʻia ka lāʻau lapaʻau a mālama ʻia wale nō e nā limahana lapaʻau i mākaukau ʻia.

Ma mua o ke kau ʻana, pono ke ʻokiʻoki me ka hāpau a me ka hue me ka lāʻau lapaʻau mai ka pahu ai a lawe ʻia i ka pā lumi (30-50 mau minuke e pono ai).

Mālama i ka ʻeke me Octreotide Depot i kū pololei. Ka hoʻoweliweli ʻana i ka vial māmā, e hōʻoia i ka lalo o ka lyophilisate holoʻokoʻa ma lalo o ka vial.

E wehe i kahi kīʻaha me ka syringe, hoʻopili i kahi nūpepa 1.2 mm x 50 mm i ka ʻāʻā ma e ʻohi ai i ka pila.

E wehe i ka ampoule me ka lapalapa a kau i loko o ka syringe nā kiko āpau o ka ampoule me ka uku pahu, hoʻonoho i ka syringe i kahi pāʻauʻau o 3.5 ml.

Hoʻokuʻu i ka pāpale palika mai ka panakī e loaʻa ai ka lyophilisate. Hoʻopilikia i nā mea pani kīʻaha o ke kīʻaha me kahi ʻōnaʻi waiʻona.Hoʻokomo i ka lāʻau pono i loko o ka pahu lyophilisate ma waena o ka pahu kaʻa kīpē a hoʻokomo pono i ka solvent ma ka ʻaoʻao o ka pā o ka vial me ka hoʻopā ʻole ʻana i nā mea o ke kīʻaha me ka pūpū. Hoʻokuʻu i ka syringe mai i ke kīʻaha.

Pono ka neʻe a kū i ka neʻe a hiki i ka hoʻomohala piha ʻana o ka puna me ka lyophilisate a me nā palapala hoʻomanee (e pili ana i 3 a 5 mau minuke). A laila, me ka ʻole o ka huli ʻana i ka hue maʻa, pono ʻoe e nānā no ka hele ʻana o ka lyophilisate maloʻo ma nā paia a i lalo o ka hue. Inā loaʻa nā kala maloʻo lyophilisate, e waiho i ka pākuʻi a hiki i ka saturated piha.

Ma hope o ka hōʻoia ʻana ʻaʻole i ke koena o ka lyophilisate maloʻo, pono e hoʻopili pono ʻia nā kiko o ka vial i loko o kahi neʻe no ka 30-60 kekona a hiki i kahi hoʻokō homogeneous. ʻAʻole a kīwī paha i lohi paha i ka kīʻaha, no ka mea, he hopena kēia i ka pau ʻana o ka pīpī a me ka hoʻokipa ʻaʻole pono.

E hoʻopili koke i ka pūlima ma o ka mea pani kele i ka pahu. A laila e hoʻohaʻahaʻa i ka pauku ʻanuʻu a, ma ka hoʻopiha ʻana i ke kīʻaha ma ke kihi o 45 degere, e huki koke i ka puhū ʻana i loko o ka syringe. Mai kiʻoki i ka hue inā paʻi. ʻO kahi liʻiliʻi o ka lāʻau lapaʻau e noho mau ma luna o nā paia a i lalo o kahi pākahi. ʻO ka hoʻohana ʻia no ke koena ma luna o nā paia a i lalo paha o ka hue.

Ma hope koke o ka hōʻiliʻili ʻana ʻana o ka puhoi, ke kahili ʻana i ka pono me ka poha ka ʻulaʻula me ka pāpala me ka pavilion kākele (0.8 x 40 mm), e huli pono i ka syringe a wehe i ka lewa mai ka ʻāʻā.

ʻO ka Octreotide Depot Suspension e mālama koke ʻia ma hope o ka hoʻomākaukau.

ʻAʻole hui ʻia nā Octreotide Depot Suspension me nā lāʻau lapaʻau ʻē aʻe i kēlā mau syringe like.

E hoʻohana i kahi swab i mea inu wai e hoʻomaʻemaʻe ai i ke kahua o ka injection. Hoʻokomo i ka pulika nui i loko o ka puʻu gluteus maximus, a laila hoʻihoʻi iki i ka syringe plunger i mea e hōʻoia ʻole ai kekahi pōʻino i ka moku. E hoʻolauna i ka hoʻolanʻi intramuscularly mālie me ke kaomi mau ʻana i ka plueer syringe.

Inā e hoʻokomo ia i kahi o ke koko, e pono ke hoʻololi ʻia ka wahi o ka injection.

Ke hoʻokomo nei i kahi pū, pono e hoʻohuli me kahi lole o ke anawaena a like.

Me nā ʻōkuhi helu hou, pono ke loli ka ʻaoʻao hema a ʻākau.

Nā hopena hopena

Hōʻike ʻia nā hopena ʻino e pili ana i ka maʻamau o nā mea i hiki mai i ka ʻatikala: pinepine pinepine (≥1 / 10), pinepine (≥1 / 100,  1/10), i kekahi manawa (≥1 / 1000, 1 / 100), kaʻaila (= ≥ 1/10000, 1 / 1000), loaʻa pinepine (1 / 10000), me nā leka a kekahi.

- ʻeha hōʻeha o ka ʻōpū, bloating, constipation, ʻōpala

- nā hopena kūloko i ka hihia o ka hoʻokele subutanutan (hōʻeha, ʻōpū, ʻulaʻula, ʻā ʻia a me ka puhi ʻana)

-hypothyroidism, thyroid dysfunction

- dizziness, dyspnea, asthenia

- bradycardia, tachycardia, cholecystitis, pohō lauoho

- ʻūwē ʻūpū, ʻeha

hoʻomahuahua, hoʻomakino, hana i nā gallstones (me ka hoʻohana lōʻihi o Octreotide-Depot), cholecystitis, biliary sludge, steatorrhea (ʻoiai ke kīlei ʻana o ka momona me nā feces e piʻi, ʻaʻohe hōʻailona hōʻike e lōʻihi ka mālama ʻana me Octreotide-depot. ma muli o ka malabsorption (malabsorption)), nā mea i like me ke aʻalopona o nā mea aʻeha o ka aʻalā: hele i ka ulu ʻana, hōʻeha nui i ka ʻōpū o ka epigastric, ka mākene o ka pā o ka ʻōpū, ka ʻalike "pale".

pancreatitis akula, anorexia, mau keʻa pinepine, hepatitis mākia me ka cholestasis, hyperbilirubinemia, hoʻonui i ka alkatine phosphatase, gamma glutamyl transferase, transaminases, thrombocytopenia, hyperkalemia

hypertension arterial (me ka hoʻohana o ka lōʻihi)

Hiki ke hoʻemi ʻia ka paʻakikī o nā hopena i ka wā inā hoʻohana ʻoe i kahi hoʻonā o ka lumi lumi, a e komo i kahi lihi liʻiliʻi o kahi hopena ʻoi aku ka nui.

ʻO nā hōʻike pili ʻana i ka hoʻolaha

anaphylaxis, kūlohelohe maʻi, urticaria rash

pancreatitis kaulike, hepatitis mākia, hepatitis cholestatic, cholestasis, hoʻōla o ka ʻili, jaundice cholestatic

Hoʻopili i nā lāʻau lapaʻau

ʻO ka Octreotide e hōʻemi ana i ka laweʻana o ka cyclosporine, e hoʻohiolo ana i ka lilo o ka cimetidine. Ke hoʻoponopono ʻana i ka hoʻoponopono ʻia o ka dosage i hoʻohana pinepine ʻia i nā diuretics, nā beta-blockers, "lohi" a me nā mea laikini kalima, insulin, a me ka lāʻau hypoglycemic waha.

Me ka hoʻohana like ʻana o octreotide a me bromocriptine, hoʻonui i ka bioavailability o ka hope.

ʻO nā lāʻau hoʻohālikelike e nā enzymes o ka pūnaehana cytochrome P450 a me ka pālahalaha ʻoi aku ka palena liʻiliʻi e pono ai e kuhikuhi me ka mālama.

Nā ʻōlelo kikoʻī

Me nā tumors pituitary huna huna GR, mālama pono i nā poʻe maʻi e loaʻa ana iā Octreotide Depot e pono, no ka mea hiki ke hoʻonui ʻia i ka nui o nā tumors me ka hoʻomohala ʻana i nā hōʻeha koʻikoʻi e like me ka hoʻopili ʻana i nā kula kūleʻa. I kēia mau hihia, pono e noʻonoʻo ʻia ka pono o nā ʻano lāʻau ʻē aʻe.

Pono ka nānā ʻana o ka maʻi thyroid i nā maʻi e hoʻomanawanui ana i ka mālama mau ʻia me Octreotide Depot.

Ua hōʻike ʻia nā hōʻike e pili ana i ka bradycardia me octreotide. I kēia mea, pono ia e hoʻoponopono i ka ʻawaʻawa no nā lāʻau e like me ka beta-blockers, nā alaka a me nā mea hoʻohana i hoʻohana ʻia no ka mālama ʻana i ka pae wai-electrolyte.

Ma 10-20% o nā maʻi e loaʻa ana i ka Octreotide Depot no ka manawa lōʻihi, hiki i ke ʻano o nā pali i ka gallbladder, no laila, e pono e mālama ʻia i kēia mau ʻōlelo aʻoaʻo.

Nā alakaʻi no ka hoʻokele o nā maʻi i ka wā o ka mālama ʻana me ka Octreotide Depot e pili ana i ka hoʻokumu ʻia ʻana o nā pōhaku o ka gallbladder.

Ma mua o ka manawa i koho ʻia ai ʻo Octreotide Depot, pono i ka mea maʻi ma mua o ka hoʻokolokolo ʻana i ka ultrasound mua o ka maʻi pēpē.

i ka wā o ka mālama ʻana me Octreotide-Depot, pono e nānā ʻia ka nānā ʻana o ka ultrasound i ka maʻi o ka gallbladder, ʻoi aku ka maikaʻi o nā manawa 6-12 mau mahina,

inā i ʻike ʻia nā pōhaku ma mua o ka hoʻomaka ʻana o ka mālama ʻana, pono e loiloi i nā pōmaikaʻi o nā pono o Octreotide-Depot e hoʻohālikelike ʻia i nā hopena hiki paha ke pili pū me ka wā i loaʻa i nā gallstones. ʻAʻohe mea iʻike i kekahi hopena maikaʻi loa o Octreotide Depot ma ke ala a i ʻole ka prognosis o kahi maʻi gallstone e noho nei.

Hoʻokele i nā mea maʻi i kūkulu ʻia nā pōhaku gallbladder i ka wā mālama me ka Octreotide Depot.

a) Nā pōhaku kilipani Asymptomatic.

Hiki ke hoʻokaʻawale ʻia a hoʻohana ʻia paha ka hoʻohana ʻana o Octreotide Depot - e like me ka loiloi ʻana i ka pae pōmaikaʻi / ʻokoʻa. I kekahi hihia, ʻaʻohe pono e hana i nā mea ʻē aʻe ma mua o ka hoʻomau ʻana i ka nānā, e hana ʻoi aku ka ʻoi aku inā pono.

b) ʻO nā pōhaku a Gallbladder me nā hōʻailona lapaʻau.

Hiki ke hoʻokaʻawale ʻia a hoʻohana ʻia paha ka hoʻohana ʻana o Octreotide Depot - e like me ka loiloi ʻana i ka pae pōmaikaʻi / ʻokoʻa. I kekahi hihia, pono e mālama ʻia ka mea maʻi i nā ala like ʻole e like me nā mea ʻē aʻe o ka maʻi gallstone me nā hōʻike olakino. Hoʻomaopopo ka lāʻau lapaʻau i ka hoʻohana ʻana o nā mea hoʻohui o ka hui o ka bile acid (no ka laʻana, ka chenodeoxycholic acid ma kahi maʻa o 7.5 mg / kg i kēlā lā i ka hui pū me ka ursodeoxycholic acid i ka hopena like) ma lalo o ke alakaʻi ʻana a ultrasound a hiki i nā nalowale nā ​​pōhaku.

ʻO nā mea maʻi me ka insulinomas i mālama ʻia me Octreotide-Depot e loaʻa i ka nui o ka hōʻeha a me ka lōʻihi o ka hypoglycemia (ʻo kēia ka hopena o ka hopena inhibitory nui ma ka huna ʻana o GH a me glucagon ma mua o ka honi ʻana o ka insulin, a me ka lōʻihi o ka manawa o ka hopena o ka inhibitory ma ka huna ʻana o ka insulin). Pono nā mea maʻi e nānā pono ʻia i ka hoʻomaka ʻana o ka mālama ʻana me Octreotide-depot, me kēlā me kēlā me kēia hoʻololi i ke ʻano o ka lāʻau. ʻO ka hoʻohaʻahaʻa nui i ka hoʻoliʻi o ka glucose i ke koko hiki ke hoʻāʻo e hōʻemi i ka hoʻokele pinepine ʻana o Octreotide Depot.

I ka wā o ka hoʻokaʻawale ʻana mai nā varicose veins o ka esophagus a me ka ʻōpū i nā mea maʻi me ka cirrhosis, hoʻonui ʻia ke ala o ka hoʻomohala ʻana i ka diabetes mellitus e pili ana i ka maʻi, a me nā hoʻololi ʻana i nā koi o ka insulin i nā mea maʻi me ka maʻi mellitus, no laila, ma kēia mau mea, pono ka mālama ʻana o ka ʻōnaehana o ka glucose glucose.

I nā maʻi me ka maʻi diabetes type, hiki i ka Octreotide Depot ke hōʻemi i ka pono o ka insulin. I ka poʻe maʻi me ka diabetes mellitus a me ka diabetes mellitus type 2 me kahi huna huna o ka insulin i mālama ʻia, hiki ke alakaʻi i ka Octreotide Depot e hiki ai i kahi hoʻonui postprandial i loko o nā glucose koko.

I kekahi mau mea maʻi, hiki i ka octreotide ke hoʻololi i ka kao ʻana o ka momona i loko o nā ʻōpū, hoʻemi i ka pae o ka vitamin B12 i loko o ke koko a lilo i ka haʻalele ʻana mai nā ʻano o nā waiwai o ka hōʻike ʻo Schilling.

ʻŌpū a me ka lactation

ʻAʻoheʻike me ka lilo o ka lāʻau lapaʻau i ka wā hapai, ma ia mau mea e kuhikuhi ʻia ai ka lāʻau lapaʻau e like me nā hōʻike kūʻokoʻa loa. I ka wā o ka mālama ʻana me Octreotide Depot, pono e hōʻoki ʻia ka umauma.

Hoʻohana ʻo Pediatric

ʻAʻoheʻike i loaʻa me ka Octreotide Depot i nā keiki.

Nā hiʻohiʻona o ka hopena o ka lāʻau lapaʻau ma ka hiki ke hoʻokau i kahi kaʻa a lawelawe paha

ʻO kekahi mau hopena o ka hopena o Octreotide Depot e hoʻopilikia i ka hiki ke lawe i nā kaʻa a me nā mīkini e pono ai e hoʻonui nui i ka nānā a me ka wikiwiki o ka hopena psychomotor.

Hoʻohui Kūʻai Kūʻai

Ka inoa a me ka ʻāina o nā mea hana

Deco Company LLC, Hui Pū ʻIa Lūkini

129344, Moscow, st. Yenisei, kūkulu hale 3, kūkulu hale 4

Ka inoa a me ka ʻāina o ka mea hoʻopaʻa inoa palapala

Farm Synthesis CJSC, Ka Lūkini Kūlana

111024, Moscow, Kabelnaya 2-ya alanui, hale 2, p 9

ʻO ka noho ʻana o kahi hui e ʻae ana i nā koi mai nā mea kūʻai aku ma ka maikaʻi o nā huahana (nā huahana) i ka Repubalika o Kazakhstan

Raifarm LLP (Raifarm)

KA HOOMANA O KAZAKHSTAN, Almaty, st. Timiryazev 42, bldg. 15/3 V.

Nā kiʻi 3D

ʻO ka wehewehe ʻana i ke ʻano dosis

ʻO ka ʻāpana Lyophilized a i ʻole porous, i hoʻopaʻa ʻia i loko o kahi papa papa ke keʻokeʻo a i ʻole keʻokeʻo me kahi ʻāpana melemele.

Haʻalele wai kaila poloka.

Hoʻopaʻa hou ʻia he hopi i kahi keʻokeʻo a i keʻokeʻo paha me kahi keʻokeʻo i kahi melemele.

Nā Hōʻikeʻike Octreotide Depot

ke lawa pono ana o nā hōʻike o ka maʻi e lawe ʻia ana e ka hoʻokele sc octreotide,

i ka haʻalele ʻole o ka hopena kūpono o ka hoʻomaʻamaʻi ʻana a me ka maʻi radiation

hoʻomākaukau e hoʻomākaukau no ka maʻi maʻi,

no ka mālama ʻana ma waena o nā papa o ka maʻi radiation a hiki i ka hopena mau loa,

i ka poʻe maʻi maʻi.

ʻO ka maʻi maʻi o endocrine o ka gastrointestinal tract a me ka pancreas:

nā mea hoʻonani maʻi me nā mea hoʻonā o nā maʻi carcinoid,

gastrinomas (Zollinger-Ellison syndrome),

glucagonomas (e kāohi ai i ka hypoglycemia i ka wā preoperative, a no ka mālama pono ʻana)

somatoliberinomas (mau māka i hōʻike ʻia e ka overproduction o ka ulu ʻana o ka hormone hoʻokuʻu i hoʻokuʻu i ke ʻano).

ʻO ka hopena o ka maʻi prostate-pale prostate: ma ka ʻāpana o nā hui hoʻohui i ke kua o ke kaupaona ʻana a i ʻole ke kau ʻana i ka lāʻau.

ʻO ka paleʻana i ka hoʻomohalaʻana o ka pancreatitis postoperative: me nā hana ʻoi loa ma ka ʻōpū o ka ʻōpū ma ka ʻōpū o thoracoabdominal (komoe pili ana i ke kanesa o ka ʻōpū, esophagus, colon, pancreas, prim a me ka lua o ke ake o ka ate).

ʻŌpū a me ka lactation

ʻAʻoheʻike i loaʻa me Octreotide Depot i ka wā hapai a i ka wā o nā umauma. No laila, i ka wā hāpai, ua kuhikuhi ʻia ka lāʻau lapaʻau inā wale nō paha e pono ka pōmaikaʻi i ka makuahine i ka ʻoi ʻana o ka maʻi i ka ʻōpū. ʻAʻole kūkākūkā ʻia ka wā lohi e hoʻohana i ka lāʻau i ka wā lactation.

Mea hana

ʻO ka ʻoihana ka mea nona ka palapala hoʻopaʻa inoa: Farm-Sintez JSC.

Kūlana kānāwai: 111024, Lūkia, Moscow, ul. Laila 2, p. 46.

Kaʻina: 121357, Lūkia, Moscow, ul. Vereyskaya, 29, p 134, keena A403, A404.

Kelepona: (495) 796-94-33, fax: (495) 796-94-34.

Ke ʻae nei ka hui i nā kuhi: Farm-Synthesis JSC.

Ka hana lāʻau lapaʻau

ʻO ka lāhike ʻo Octreotide-Depot kahi puka waiola octreotide no ka lōʻihi o ka hoʻokele intramuscular, e maopopo ai ka mālama ʻana i ka hoʻomau ʻana o ka paʻa o ka ʻona octreotide i loko o ke koko no 4 wiki. ʻO Octreotide kahi hoʻomehana pathogenetic no nā maʻi kī e hōʻike ikaika ana i nā mea hoʻokomo somatostatin. ʻO Octreotide kahi hana octapeptide synthetic o kahi derivative o ke kūlohelohe o ka somatostatin a he mau hopena o ka pharmacological like, akā he lōʻihi o ka lōʻihi o ka hana. Ke pale aku nei ka lāʻau lapaʻau i ka mea hoʻonaninani me ka pathologically i hoʻonui ʻia i ka hormone ulu (GH), a me nā peptides a me ka serotonin i hana ʻia i loko o ka gastro - entero - pancreatic endocrine system.

I nā poʻe olakino olakino, ʻoctreotide, e like me somatostatin, ke kāohi nei i ka mea huna o GR e loaʻa e ka arginine, ka hana kino a me ka hypoglycemia insulin, nā mea huna o ka insulin, glucagon, gastrin a me nā peptides o ka ʻōnaehana endocrine gastro-entero-pancreatic, ka mea i hoʻoulu ʻia e ka ʻai, a me ka hoʻoulu ʻana i ka insulin. ʻO Arginine, kahi huna huna thyrotropin i hoʻokumu ʻia e kāuroliberin. ʻO ka hopena hana hōʻeuʻeu i ka mea huna o GR i octreotide, i ka ʻokoʻa ʻana i ka somatostatin, ua hōʻike ʻia i kahi nui loa ma mua o ka honi ʻana i ka insulin. ʻAʻole i alakaʻi ʻia ke octreotide e ka hanana me ke ʻano o ka hypersecretion o nā hormones e ka maikaʻi ʻona o ka pane.

I ka poʻe maʻi me ka acromegaly, hāʻawi ka hoʻokele o ka puka o ka octreotide i ka nui o nā hihia i ka hoʻomau mau nei o ka neʻe o ka GH a me ka hoʻokaʻawale ʻana i ka ʻike o ka insulin-like growth factor 1 / somatomedin C (IGF-1).

I ka hapa nui o nā poʻe maʻi me acromegaly, ʻo ka depot form o octreotide e hōʻemi nui loa i ka hōʻeha o nā hōʻailona e like me ke poʻo, hōʻuluʻulu, paleka, ʻeha, ʻehaʻeha i nā iwi me nā ʻōpū, peripheral neuropathy. Hōʻike ʻia ʻo ka mālama ʻana me ke ʻano o depot o octreotide i nā mea maʻi o ka poʻe maʻi me ka adenomas huna e hūnā ana i ka GH ka hopena o ka hōʻemi o ka nui o ka ʻōpū.

Me nā ʻoihana endocrine secretory o ka gastrointestinal tract (GIT) a me nā pancreas, ka hoʻohana ʻana i ka puka octreotide depot e hāʻawi mau i ka kiaʻina mau i nā hōʻailona nui o kēia mau maʻi.

ʻO kahi papa depot o octreotide ma kahi o 30 mg i kēlā me kēia 4 wiki e hoʻohiolo i ka ulu ʻana i nā maʻi i nā mea maʻi me ka hūnā ʻole a me ka huna ʻole ʻia (metastatic) o ka maʻi neuroendocrine o ka ʻili, iliac, makapō.
ka piʻi kolu, kahi nūhou a me nā ʻāpana vermiform, a i ʻole metastases o nā koikoi neuroendocrine me ko ka maka ʻole. Loaʻa ka lāʻau lapaʻau i ka hoʻonui ʻana i ka manawa i ka holomua, ʻo ia no ka hūnā huna a ʻaʻole ʻole e hūnā ʻia i nā puku neuroendocrine.

I loko o nā maʻi carcinoid, hiki i ka hoʻohana ʻana o octreotide ke alakaʻi i ka hōʻemi o ka hōʻeha o nā hōʻailona o ka maʻi, e like me nā kaʻa wela a me nā maʻi laʻa. I nā kūlana he nui, ʻo ka holomua ʻana o ka maʻi me ka ʻimi ʻia
ʻO ka hoʻohemo ʻana o ka kukuna plasma serotonin a me ka hoʻopiʻi ʻana o ka 5-hydroxyindoleacetic acid i ka urine.

I loko o nā hua i hoʻākāka ʻia e ka hyperproduction o kahi peptide ʻōpū vasoactive (VIPoma), ka hoʻohana ʻana o octreotide i ka hapanui o nā maʻi e alakaʻi i kahi kaho o ka ʻōpū huna huna, ʻo ia ka mea o kēia ʻano, ka mea, e alakaʻi i ka hoʻomaikaʻi ʻana i ka maikaʻi o ke ola o ka mea maʻi. I ka manawa like, aia ke emi o ka hoʻohālikelike neʻe i loko o ke kaulike electrolyte, no ka laʻana, hypokalemia, kahi e ʻae ai iā ʻoe e hoʻopau i ka enteral a me nā palapala makua no ka wai me nā electrolytes. Wahi a tomography i hoʻohālikelike ʻia, i kekahi mau mea maʻi he lohi a hemo paha ka holo ʻana o ka ʻōpū, a me ka emi ʻana o kona nui, ʻo ia hoʻi nā metastases ate. Hoʻololi pinepine ʻia ka hoʻomaikaʻi ʻana i ka maʻi me ka hōʻemi (a hiki i nā waiwai maʻamau) i ka ʻike ʻana o ka peptide intestinal peptide (VIP) i loko o ka plasma.

Me nā glucagonomas, ʻo ka hoʻohana ʻana i ka octreotide i ka hapanui o nā hihia e alakaʻi i kahi ʻike nui ʻana i nā pihi migratory necratizing, ka mea e ʻano o kēia kūlana. ʻAʻohe o nā hopena nui o Octreotide e pili i ka nui o ka maʻi mellitus, i mālama pinepine ʻia me ka glucagonomas, a maʻamau ʻaʻole paha.
e hōʻemi i ka pono o ka insulin a me ka lāʻau hypoglycemic oral. I nā poʻe maʻi me ka maʻi ʻaʻai, ʻo ka octreotide e hōʻemi i loko o ia mea, i hui pū ʻia e ka piʻi ʻana o ka nui o ke kino. Me ka hoʻohana ʻana o octreotide, kahi emi wikiwiki i ka neʻe o ka glucagon i loko o ka plasma e ʻike pinepine ʻia, akā naʻe, me ka hoʻōla lōʻihi, ʻaʻole mau kēia hopena. I ka manawa like, noho mau ka hoʻomaʻamaʻa like me ka lōʻihi no ka lōʻihi.

I loko o ka gastrinomas / Zollinger-Ellison syndrome, octreotide, i hoʻohana ʻia me ka monotherapy a i hui pū ʻia me nā blockers recepti a Ng-histamine a me nā pale kiaʻi proton, hiki ke hōʻemi i ka hoʻokumu ʻia o ka waikila hydrochloric i loko o ka ʻōpū a alakaʻi i ka hoʻomaikaʻi ʻana i ka maʻi, e komo ai e pili ana i ka huʻehaʻe. Hiki nō iā ia ke hōʻemi i ka ʻāʻī a me nā hōʻailona ʻē aʻe, ka pili pū me ka synthesis o nā peptides e ka ʻōpū, me nā Nā kuikahi. Ma kekahi
i nā hanana, ua ʻike ʻia ka emi ʻana o ka ʻāʻī o ka gastrin i loko o ka plasma. Ma nā mea maʻi me ka insulin, ua hōʻemi ʻia ka octreotide i ka ʻaila o ka immunoreactive insulin i ke koko. I nā mea maʻi me nā maʻi ʻoi aku, hiki i ka octreotide ke mālama i ka hoʻihoʻi a me ka mālama o ka normoglycemia i ka wā preoperative. I nā maʻi me nā maʻi o nā maʻi ʻōpiopio a me nā maʻi lahilahi, e hoʻomaikaʻi paha ka mana glycemic me ka ʻole like ʻole
ka hoʻolōʻihi lōʻihi ʻana i loko o ke kaila o ka insulin i ke koko.

I ka poʻe maʻi me nā ʻāpana ʻeha e hōʻike ana i ka ulu ʻana o ka hormone hoʻoulu e hoʻoulu ai i ka wai (somatoliberinomas), e hōʻemi ana ka octreotide i ka nui o nā hōʻailona acromegaly. ʻO kēia, ʻike, i pili me ka kaohi ʻana o ka mea huna i ka mea hoʻokuʻu i ka ulu o ka ulu ulu a me ka GH ponoʻī. I ka wā e hiki mai ana, hiki i ka hōʻemi ʻana i ka nui o ka nui glandary, i hoʻonui ʻia ma mua o ka mālama ʻana.

I nā mea maʻi me ka maʻi prostate hormone pale (HGRP), ka loko o nā pū neuroendocrine e hōʻike ana i ka hopena o ka hopena somatostatin e pili ana i ka octreotide (SS2 a me nā ʻano SS5), e hoʻoholo ana i ka hoʻowalewale o ka ʻōpala i ka octreotide. ʻO ka hoʻohana ʻana i ka lāʻau Octreotide-Depot i hui pū me dexamethasone e kū'ē i ke kua ʻana o ka blockade androgen (lāʻau a me ka hōʻino ʻana paha) i nā mea maʻi me HGRP e hoʻihoʻi i ka naʻau i ka therapy hormone a alakaʻi i ka emi ʻana o ka antigen spate (PSA) ma mua o 50% o nā maʻi.

I nā maʻi me HGRG me nā metastases o nā iwi, hui pū ʻia kēia mea e ka hopena me ka hopena analgesic i haʻi ʻia. Eia kekahi, i nā mea maʻi a pau i pane aku i nā lāʻau hoʻohui me ka lāʻau lapaʻau Octreotide-depot, maikaʻi ke ola o ke ola a me ka maʻi maʻi maʻi median me ka maikaʻi loa.

Nā ʻōkuhi ʻO Octreotide-Depot

I ka mālamaʻana o ka acromegaly:

• ke lawa pono ana o nā hōʻike o ka maʻi e lawe ʻia ana e ka hoʻokele sc octreotide,
• i ka haʻalele ʻole o ka hopena kūpono o ka hoʻomaʻamaʻi ʻana a me ka maʻi radiation
• hoʻomākaukau e hoʻomākaukau no ka maʻi maʻi,
• no ka mālama ʻana ma waena o nā papa o ka maʻi radiation a hiki i ka hopena mau loa,
• i ka poʻe maʻi maʻi.

I ka mālamaʻana i nā hana endocrine o ke kumu gastrointestinal a me pancreas:

• nā mea hoʻonani maʻi me nā mea hoʻonā o nā maʻi carcinoid,
• nā hale hana insulin
• VIPoma
• gastrinomas (Zollinger-Ellison syndrome),
• glucagonomas (e kāohi ai i ka hypoglycemia i ka wā preoperative, a no ka mālama pono ʻana)
• somatoliberinomas (mauʻano i hōʻike ʻia e ka overproduction o ka ulu ʻana i ka hormone hoʻokuʻu i hoʻokuʻu ʻia).
• ka mālama ʻana i nā mea maʻi me ka hūnā a me ka ʻole e hūnā i nā maʻi neuroendocrine o ka ʻōpala o ka ʻili, ka ileum, makapō, ke kīwaha, ka piʻi kuikahi a me ka hoʻopili, a i ka metastases o nā mea ʻoi neuroendocrine me ka manaʻo ʻole.

I ka lapaʻau ʻana o ka maʻi prostate-pale prostate:

• ma ka ʻāpana o nā hui hoʻohui i ke kua o ke kaupaona ʻana a i ʻole ke kau ʻana i ka lāʻau.

I ka paleʻana o ka pancreatitis postoperative:

• me ka hāhā o nā ʻōpū ākea a me nā wawaʻi thoracoabdominal (me ka mākaukau o ka ʻōpū o ka ʻōpū, esophagus, colon, pancreas, primer a me ka lua o ka hōʻeha hōʻeha i ka ʻōpū).

Ka hoʻoponopono ʻia ʻana

Pono ka lāʻohana o Octreotide-Depot e hana pū ʻia ma loko o ka intramuscularly hohonu (IM) wale nō, i loko o ka puʻu gluteus. Me nā ʻōkuhi helu hou, pono ke loli ka ʻaoʻao hema a ʻākau. Pono koke e hoʻomākaukau i ka hoʻopiʻi ʻana ma mua o ka paʻi ʻana I ka lā o ka inikua, hiki ke mālama ʻia i ke kīʻaha me ka lāʻau lapaʻau a me ka ampoule me ka pulima i ka mālama ʻana i ka lumi.

I ka loaʻa ʻana o ka acromegaly i nā mea maʻi no ka s / c hoʻokō o ka octreotide e hāʻawi i ka kaona o ka nui o nā hōʻike ʻana o ka maʻi, ka ʻōlelo mua ʻana i kēlā me kēia lāʻau no ka make ʻana ʻo Octreotide-Depot he 20 mg kēlā me kēia 4 hebedoma no 3 mau mahina. Hiki iā ʻoe ke hoʻomaka i ka mālama ʻana me Octreotide-Depot ma ka lā ma hope o ke kahie s / c hope o octreotide. I ka wā e hiki mai ana, e hoʻoponopono ʻia ka ʻomaʻi ʻana i nā mea pili i ka serum o GR a me IGF-1, a me nā hōʻailona maʻi. Inā ma hope o 3 mau malama o ka mālama ʻana ʻaʻole hiki ke hoʻokō i kahi hopena olakino a me ka hopena biochemical (ma ke ʻano he nui loa, inā e pili ana ke kāʻei o GR ma luna o 2.5 μg / L), hiki ke hoʻonui ʻia i kēia hāpana ma 30 mg lawelawe ʻia i kēlā me kēia 4 hebedoma.

I nā hihia i hala ma hope o 3 mau lā o ka mālama ʻana me Octreotide-Depot ma ke ʻano o 20 mg, kahi hōʻemi mau
serum GH kahe ma lalo o 1 μg / l, normalization o ke kaohi ʻana o ka IGF-1 a me ka nalo ʻana o nā huli hoʻohuli o ka acromegaly, hiki iā ʻoe ke hōʻemi i ka nui o ka lāʻau no ka lāʻau Octreotide-depot i 10 mg. Eia nō naʻe, ma kēia mau mea maʻi e loaʻa ana ka liʻiliʻi liʻiliʻi o Octreotide Depot, nā hana serum o GR a me IGF-1, a me nā hōʻailona o ka maʻi, pono e mālama pono ʻia.

ʻO ka poʻe maʻi e loaʻa ana i kahi kaomi paʻa o Octreotide-Depot e pono e hoʻāʻo ʻia i kēlā me kēia 6 mahina no ka nānā ʻana o GH a me IGF-1.

ʻO ka mea maʻi no ka mea e hoʻomaʻamaʻi ʻana i ka lāʻau lapaʻau a me nā maʻi radiation hiki ʻole ke kūleʻa i ka maʻi, a no ka poʻe maʻi e pono ai i ka hoʻolālā pōkole ma waena o nā papa o ka radiation radiation a hiki i ka hoʻomohala ʻana i kona hopena piha, ʻo ia ka mea e hana ʻia ai he papa hoʻokolokolo o ka mālama ʻana i nā s / c injections o octreotide i mea e loiloi ai i kāna ka hopena a me ka hoʻomanawanui nui, a ma hope wale nō o kēlā hoʻololi i ka hoʻohana ʻana i ka lāʻau no ka make ʻana ʻo Octreotide-depot e like me ke ʻano i luna aʻe.

I ka loaʻa ʻana o nā hua o endocrine o ka ʻokiʻoki a me ka pancreas i nā mea maʻi no ka sc management o octreotide e hāʻawi pono i nā mākaʻi o nā hōʻike a ka maʻi, ka ʻōlelo a ka poʻe i hāʻawi ʻia ma Octreotide-Depot he 20 mg i kēlā me 4 wiki. E hoʻomau ʻia ka hoʻokele sc o octreotide no 2 mau pule aʻe ma hope o ka hoʻokō mua ʻana i ka lāʻau ʻo Octreotide-Depot.

I ka poʻe maʻi ʻaʻole i loaʻa i mua o sperm octreotide, ke manaʻo ʻia e hoʻomaka ʻia ka mālama ʻana me ka hoʻōla ʻana o sct. Ma hope wale iho o kēia, ua kauoha ʻia ka lāʻau lapaʻau Octreotide-depot e like me ka hoʻolālā ma luna.

I ka hihia a ʻo ka therapy me Octreotide-Depot no 3 mau mahina e hāʻawi pono i ka mākaʻi o nā hōʻike lapaʻau a me nā hōʻailona olakino o nā maʻi, hiki ke hoʻemi i ka nui o ka huaʻāina o Octreotide-Depot i 10 mg,
i koho ʻia i kēlā me kēia 4 pule. I nā hihia i hala ma hope o 3 mau lā o ka mālama ʻana me Octreotide-Depot, ʻoiai wale nō ka hoʻonui ʻana i ka hoʻomaikaʻi ʻana, hiki ke hoʻonui ʻia ka nui i ka 30 mg i kēlā me 4 wiki. E kūʻē i ke kuʻuna o ka lapaʻau me Octreotide-Depot, i kekahi mau lā hiki ke hoʻonui ʻia i nā hōʻike kulana maʻi ʻano endocrine tumors o ka gastrointestinal tract a me ka pancreas. I kēia mau hihia, ua hāpai ʻia kahi lawelawe s / c o ka octreotide i kahi maʻa i hoʻohana ʻia ma mua o ka hoʻomaka ʻana o ka hoʻōla me ka Octreotide Depot. Hiki ke hana i kēia ma nā mahina 2 mua o ka mālama ʻana a hiki i ka ʻike ʻana o nā ʻekepili o octreotide i ka plasma.

ʻO nā mea huna a me ka huna ʻole ʻole (metastatic) ʻo nā ʻoiʻi neuroendocrine o ka ʻili o ka ʻili, ka ileum, makapō, piʻi i ke alo lāʻau, transvers colon a me ka appendix, a me ka metastasis o ka maʻi neuroendocrine me kahi palaka mua: ʻo ke ʻano i ʻōlelo ʻia ʻo Octreotide Depot he 30 mg kēlā me 4 wiki. Pono e hoʻomau ka ʻomaʻomaʻo Octreotide-depot a hiki i nā hōʻailona o ka ulu ʻana i ka maʻi ʻaʻai.

I ka loaʻa ʻana o ka maʻi prostate paleʻai i ka maʻi prostate, ʻo ke ʻano neʻe i hoʻomaka mua ʻia o Octreotide Depot he 20 mg i kēlā me kēia 4 wiki no 3 mahina. Ma hope aku, hoʻoponopono ʻia ka ʻae ʻana i ka noʻonoʻo ʻana i nā kumulāʻau o ka seru PSA serum, a me nā hōʻailona kino. Inā ma hope o 3 mau lā o ka mālama ʻana ʻaʻole hiki ke hoʻokō
pono ka lāʻau lapaʻau a me ka hopena biochemical (hoʻemi ʻia ka PSA), hiki ke hoʻonui ʻia ka nui o ka 30 mg e lawelawe ʻia i kēlā me kēia 4 pule.

Hoʻohui ʻia ka lāʻau lapaʻau me ka Octreotide Depot me ka dexamethasone, i kuhikuhi ʻia ma ke ʻano me ke ʻano e pili ana i kēia kumuhana: 4 mg i ka lā no ka mahina 1, a laila 2 mg i kēlā me kēia lā no 2 mau hebedoma, a laila 1 mg i kēlā me kēia lā.

ʻO ka mālama ʻana o Octreotide-depot a me dexamethasone o nā poʻe maʻi i hoʻomaʻamaʻa mua i ka lāʻau antiandrogen therapy i hoʻohui pū ʻia me ka hoʻohana ʻana o nā mea hoʻohālike o gonadotropin-hoʻokuʻu i ka hormone (GnRH). I kēia hihia, ʻo ka maʻi o ke kikowaena o GnRH (form depot) i lawe ʻia i ka manawa 1 ma ka 4 mau pule.

E hoʻāʻo ʻia nā mea maʻi e loaʻa ana iā Octreotide Depot i kēlā me kēia mahina no ka nānā ʻana o PSA.

I nā mea maʻi me ka renal impaired, ʻāʻī a me nā mea maʻi maʻi, ʻaʻohe mea e pono ke hoʻoponopono i ka regimen dosage o ka lālani Octreotide-depot.

No ka pale ʻana i ka pancreatitis postoperative ʻoiaʻiʻo, ʻo ka lāʻau Octreotide-Depot i loko o kahi maʻa o 10 a 20 mg paha ka lawelawe ʻana i hoʻokahi manawa ma mua o 5 mau lā a ʻaʻole iʻoi aku ma mua o 10 mau lā ma mua o ka ʻoihana i manaʻo ʻia.

Na rula no ka hoomakaukau ana o ka hoopanee ana a me ka hooponopono ana i ka laau

Hoʻohana wale ʻia ka lāʻau lapaʻau i loko o ka aila. Ua hoʻomākaukau ʻia ka kāpae ʻia no ka ʻōlelo intramuscular me ka hoʻohana ʻana i ka pila i hāʻawi ʻia ma mua o ka hoʻokele ʻana. Pono e hoʻomākaukau ʻia ka lāʻau lapaʻau a mālama ʻia wale nō e nā limahana lapaʻau i aʻo ʻia.

Ma mua o ka ʻōlelo ʻana, pono ke kāpae ʻia nā ampoule me ka ipu hāpona a me ka hue me ka lāʻau lapaʻau mai loko o ka friji a lawe ʻia i ke kūmaha lumi (30-50 mau minuke e pono ai). Mālama i ka hue me ka lāʻau Octreotide-Depot kū pololei. Ka hoʻoweliweli ʻana i ka vial māmā, e hōʻoia i ka lalo o ka lyophilisate holoʻokoʻa ma lalo o ka vial.

E wehe i ka pale kuʻuna a hoʻopili i kahi nūpepa 1.2 mm x 50 mm i ka ʻāʻā maʻa e ʻohi i ka ʻai. E wehe i ka ampoule me ka hāmeʻa a waiho i loko o ka syringe nā kiko āpau o ka ampoule me ka uku pahu, hoʻonoho i ka syringe i kahi pāpaʻi o 2,0 ml. Hoʻokuʻu i ka pāpale palika mai ka panakī e loaʻa ai ka lyophilisate. Hoʻopilikia i nā mea pani kīʻaha o ke kīʻaha me kahi ʻōnaʻi waiʻona. Hoʻokomo i ka lāʻau pono i loko o ka pahu lyophilisate ma waena o ka pahu kaʻa kīpē a hoʻokomo pono i ka solvent ma ka ʻaoʻao o ka pā o ka vial me ka hoʻopā ʻole ʻana i nā mea o ke kīʻaha me ka pūpū.

Hoʻokuʻu i ka syringe mai i ke kīʻaha. Pono ka neʻe a kū i ka neʻe a hiki i ka hoʻomohala piha ʻana o ka puna me ka lyophilisate a me nā pakanika hoʻōki (no ka pili o 3-5 mau minuke). A laila, me ka ʻole o ka huli ʻana i ka hue maʻa, pono ʻoe e nānā no ka hele ʻana o ka lyophilisate maloʻo ma nā paia a i lalo o ka hue. Inā ʻike ʻia nā hopena maloʻo o ka lyophilisate, e waiho i ka vial a hiki i ka saturated piha.

Ma hope o kou ʻonikena ʻana i ka loaʻa ʻole o nā koena lyophilisate maloʻo, pono e hoʻopili pono ʻia nā kiko o ka vial i loko o nā neʻe a puni no 30-60 kekona a hiki i kahi hoʻokō homogeneous. ʻAʻole a kīwī paha i lohi paha i ka kīʻaha, no ka mea, he hopena kēia i ka pau ʻana o ka pīpī a me ka hoʻokipa ʻaʻole pono.

E hoʻopili koke i ka pūlima ma o ka mea pani kele i ka pahu. A laila ua hoʻohaʻahaʻa ʻia ka paukū ʻuma a, ma o ke kaomi ʻana i ke kīʻaha ma ke kihi o 45 degere, e huki koke i ka hoʻokuʻu ʻia ʻana i loko o ka syringe. Mai kiʻoki i ka hue inā paʻi. ʻO kahi liʻiliʻi o ka lāʻau lapaʻau e noho mau ma luna o nā paia a i lalo o kahi pākahi. ʻO ka hoʻohana ʻia no ke koena ma luna o nā paia a i lalo paha o ka hue.

Ma hope koke o ka hōʻiliʻili ʻana ʻana o ka puhoi, ke kahili ʻana i ka pono me ka poha ka ʻulaʻula me ka pāpala me ka pavilion kākele (0.8 x 40 mm), e akahele pono i ka syringe a wehe i ka lewa mai ka ʻihi.

ʻO ka hoʻokuʻuʻana i ka lāʻau no Octreotide-Depot e mālama koke ʻia ma hope o ka hoʻomākaukau. Hoʻopili ʻia kahi paʻa o ka lāʻau ʻo Octreotide-Depot me nā lāʻau lapaʻau ʻē aʻe i hoʻokahi syringe.

E hoʻohana i kahi swab i mea inu wai e hoʻomaʻemaʻe ai i ke kahua o ka injection. Hoʻokomo i ka pulika nui i loko o ka puʻu gluteus maximus, a laila hoʻihoʻi iki i ka syringe plunger i mea e hōʻoia ʻole ai kekahi pōʻino i ka moku. E hoʻolauna i ka hoʻolanʻi intramuscularly mālie me ke kaomi mau ʻana i ka plueer syringe.

Inā e hoʻokomo ia i kahi o ke koko, e pono ke hoʻololi ʻia ka wahi o ka injection. Ke keokeo nei i ka pono, e hoʻonoho me ka mea hou o ke anawaena o ka like.

Me nā ʻōkuhi helu hou, pono ke loli ka ʻaoʻao hema a ʻākau.

Loaʻa ka hopena

Nā kūloko kūloko: me ke kaʻina o i / m ʻO Octreotide-depot, hiki ke hōʻeha, hōʻemi pinepine ka nui o nā ʻūhā a me nā rashes ma ka wahi i hele ʻia.

Mai ka hanā hana ʻana: anorexia, nausea, luaʻi, hōʻeha ka ʻōpū o ka spastic, bloating, ʻano nui me ke kūlohelohe, nā kīwaha, nā huehue, steatorrhea. ʻOiai e hoʻonui nui ʻia ka momona o ka momona me nā feces, a hiki i kēia manawa ʻaʻohe ʻike e hiki ke hoʻomohala ka lōʻihi i ka mālama ʻana me ka octreotide i ka ulu ʻana o ka hemahema o kekahi mau mea kanu no ka malabsorption (malabsorption).Ma nā hanana lohi, hiki i nā mea like me ka hoʻokauʻeha o ka ʻōpū o ka ʻōpū e hiki ke hele: hiki i ka hoʻomohala holomua, ʻeha hōʻeha i ka wahi o ka epigastric, ka hoʻopaʻapaʻa ʻana o ka pā o ka ʻōpū. ʻO ka hoʻohana lōʻihi ʻana o Octreotide Depot hiki ke alakaʻi i ka hoʻokumu ʻana o nā gallstones.

Mai ka pancreas: nā maʻi maʻamau o nā maʻi pancreatitis i hoʻomohala i nā hola mua a i ʻole mau lā o ka hoʻohana ʻana i ka octreotide. Me ka hoʻohana mau ʻana, aia nā hihia o ka pancreatitis e pili ana me ka cholelithiasis.

Ma ka ʻaoʻao o ka pūpū: aia nā hōʻike ʻokoʻa i ka hoʻomohala ʻana o ka hana aho ʻole (hepatitis akene ʻole me ka cholestasis me ka normalization o transaminases ma hope o ke hoʻopau ʻana o ka octreotide), ka hoʻomohala ʻana i ka pae o ka hyperbilirubinemia, i hoʻopili ʻia e ka piʻi ʻana o ka ALP, GGT a, i kahi liʻiliʻi ʻana, nā transaminases ʻē aʻe.

Mai ka ʻaoʻao o ka metabolism: mai ka Octreotide Depot i ka hopena nui loa ma ka hoʻokumu ʻana o GR, glucagon a me insulin, hiki iā ia ke pili i ka metabolism glucose. Hiki i ka hoʻololi ʻana i ka hoʻohaʻahaʻa glucose i hope o ka ʻai ʻana. Me ka hoʻohana mau ʻana o ka haʻina o Octreotide i kekahi mau hihia, e ulu mau ka hyperglycemia hoʻomau. Ua nānā ʻia ka hypoglycemia.

ʻO nā mea'ē aʻe: ma nā hihia lohi, nalowale ka lauoho lauoho ma hope o ka hoʻokō ʻana o ka octreotide, ka hiki ʻana o bradycardia, tachycardia, pōkole o ka hanu, ʻāwili ka ʻili, anaphylaxis i hōʻike ʻia. Aia nā hōʻike kūʻokoʻa ma ka hoʻolālā ʻana o ka hopena hypersensitivity.

ʻO ka depre o Octreotide, nā ʻōlelo e hoʻohana ai: ke ʻano a me ka helu ʻana

Ua manaʻo ʻia ʻo Depreotide Depot no ka hoʻokele intramuscular.

Hoʻom hoʻomākaukau ʻia ka hana hoʻokūkū e nā limahana lapaʻau i aʻo koke ʻia ma mua o ka maʻi ʻana. No ka hoʻoili ʻana o ka lyophilisate me ka hoʻohana ʻana i ka mea hoʻolako i hāʻawi ʻia.

Na rula no ka hoomakaukau ana o ka hoopanee ana a me ka luna ana o Octreotide-depot:

1. Hoʻokuʻu i ka hoʻomākaukauʻana mai ka friji a lawe mai i ka wela o ka lumi (ʻo kēia mau maʻa he 30 a 50 mau minuke).
2. Ke paʻa ʻana i ka hue kūpaʻa māmā, e maʻalahi ke kikeke ʻana a no ka hāʻule ʻana o ka lyophilisate holoʻokoʻa i lalo.
3. E wehe i ka pēpē me ka syringe a hoʻopili i ka pono me kahi pavilion pink a 1.2x50 mm ka nui.
4. E wehe i ka ampoule me ka solvent, hoʻopiha i nā mea a pau i loko o ka syringe a hoʻonohonoho i kēiaʻano i ka 2 ml.
5. Hoʻokuʻu i ka pāpale palika mai ka lyophilized vial, disinfect the cork with an alkohol swab.
6. Hoʻokomo i ka pūwā pono o ka syringe me ka uku hoʻoheheʻe i loko o ka pahu ma waena o ka pahu pahu a me ka ninini pono ʻana i ka hoʻonā ma ka ʻaoʻao o ka pā i loko o ka pahu kuʻi ʻole i hoʻopā ʻia i nā manaʻo o ka pono.
7. Wehe i ka syringe a waiho i ke ʻano kīwila a hiki i ka laulu piha ana i ka saturated me ka hoʻokaʻawale i ke kāʻei (e pili ana i nā minuke 3-5) Ke ʻole o ka huli ʻana i ka hue, e nānā no ka lyophilisate maloʻo ma ka lalo a me nā paia. Inā ʻike ʻia ke koena paukū maloʻo, e waiho i ke kīʻaha no kekahi manawa lōʻihi a hoʻopau ʻia.
8. Ma hope o ka hōʻoia ʻana i ka lyophilisate undissolved, e kāwili pono i nā kiko o ka ipu i loko o ka neʻe poloka no 30-60 kekona, no laila ka mea hoʻomōleʻa. Mai lūlū a huli i ka hue maʻa, hiki i kēia ke alakaʻi i ka pau ʻana o nā mea i nāu, kahi mea hiki ke hoʻohana ʻia ka lāʻau lapaʻau.
9. E hoʻopili koke i ka syringe me ka lāʻau wili i loko o ke kīʻaha ma o ka pahu kalepa. Hoʻoikaika i ka ʻili huakaʻi a i kahi kihi 45 ° o ka pahu, hōʻuluʻulu mālie i ka hoʻopiʻi. ʻO kahi liʻiliʻi o ka ʻaina e noho paha ma ka lalo a me nā paia o ke kīʻaha. Hāʻawi ʻia ke koena, no laila ʻaʻole ʻoe e huli i ka hue aʻe i lalo i ka wā e lawe ai i ka lāʻau lapaʻau.
10. E hoʻopili i ka pono kuʻi i ka pūpū hoʻokomo me ka pavilion pua (0.8x40 mm), e hoʻoluli mālie i ka syringe a haʻalele i ka lewa mai ia mai.
11. Hoʻopilikia i ka wahi no ka maʻi maʻi me kahi ʻōpū wai ʻawaʻawa.
12. E hoʻokomo i ka pūlima hohonu i loko o ka molū gluteus maximus a huki hou i ka piston liʻiliʻi i mea e hōʻoia ʻole ai kekahi pōʻino i ka moku. Inā e hoʻokomo ia i kahi o ke koko, e pono ke hoʻololi ʻia ka pulupulu i kekahi o ke ano like o ka mika a ua pono ke hoʻololi ʻia ka wahi i ʻōlelo ʻia.
13. E hoʻolauna i ka hoʻokō ʻana ma o ka hoʻomau ʻana i ka plunger o ka ʻwi kani.

ʻO ka pēpē i mākaukau ʻia mai ka lyophilisate he homogeneous, keʻokeʻo a ʻeleʻele paha-keʻokeʻo.

Me nā ʻōkuhi mau, pono ke hoʻololi ʻia ka ʻūlū ʻākau a me ka hema.

ʻAʻole hoʻohui ʻia nā Octreotide Depot i ka syringe like me nā lāʻau ʻē aʻe.

Mālama mau ʻia ka lāʻau i loko o ka friji, akā ma ka lā e kau ai, e hoʻihoʻi ʻia ke kīpē me ka lyophilisate a me ka ampoule me ka solvent e mālama ʻia i ka mālama ʻana o ka lumi.

ʻO ka maʻi Acromegaly

No nā poʻe maʻi i hoʻohana ai ka octreotide pōkole (no ka subcutaneous injection) e hāʻawi i ka nui o ka mālama ʻana i nā hōʻailona o ka maʻi, hiki iā ia ke hoʻomaka i ka hoʻokō ʻana o Octreotide-depot i ka lā ma hope o ke kaina ʻana o s / c opani octreotide. Hoʻomaka lākou e mālama i ke ʻano maʻi ma waena o 20 mg i kēlā me kēia hebedoma 4, ma kēia la ka wai i hoʻohana ai ka lāʻau no 3 mau mahina. I ka wā e hiki mai ana, hoʻoponopono ke kauka i ka nui ma muli o nā hōʻike o ka maʻi maʻi a me ka piʻi ʻana o GR a me IGF-1 i ka serum koko.

Inā hiki i kahi mau mahina he 3 ʻaʻole hiki i ka hiki ke pane kūpono i kahi kūpono, e like me ka clinical and biochemical (inā paha, inā ʻaʻole i hāʻule ka nui o GR ma lalo o ka 2.5 μg / l), hoʻonui ʻia ka nui i ka 30 mg i kēlā me 4 wiki.

Inā ma hope o 3 mau malama o ka hoʻohana mau ʻana i ka nui o ka make o Octreotide-depot 20 mg, aia nō ke emi mau nei o ka paʻa ʻana o GR i ka serum koko ma lalo o 1 μg / l, ke ʻano o ka hoʻohuihui o ka IGF-1 ka hoʻōho a hoʻoliʻi i nā hōʻailona o ka acromegaly nalowale, hiki ke hoʻemi ʻia kahi ʻāpana no ka 10 mg. Pono ke hoʻomau i ka hoʻomehana ma lalo o ka mālama kiaʻi ʻana o ka ʻoihana.

ʻO nā mea maʻi e loaʻa i kahi maʻa mau i nā lāʻau lapaʻau e hiki ke hoʻoholo i ka neʻe ʻana o GR a me IGF-1 i kēlā me kēia ʻeono mahina.

I ka manawa e koi ʻia ai ka hoʻomaka ʻana o Octreotide-Depot e like me ka mālama pōkole ma waena o nā papa o ka radiation radiation, a me ka poʻe maʻi me nā maʻi ʻalani a me ka maʻi ʻaʻole e hoʻomaʻamaʻa maikaʻi loa, e aʻo ʻia e hoʻokō i kahi papa hoʻokolokolo o ka mālama ʻana me ka octreotide pōkole (no ka hoʻokele sc) i ka loiloi ʻia. hana a me ka hoʻokaʻawale ʻana o kēlā me kēia, a laila pili wale i ka Octreotide Depot e like me ke ʻano i hōʻike ʻia ma luna nei.

Hoʻohui nūhou

Hoʻololi ʻo Octreotide i ka hoʻihoʻi ʻana o ka cyclosporin mai ka ʻōpū a waiho ʻana ma kahi o ka hoʻopili ʻana o cimetidine.

Me ka hoʻohana like ʻana o octreotide a me bromocriptine, hoʻonui i ka bioavailability o ka hope.

Aia kahi mana e pili ana i ka mea hiki i nā analogat somatostatin ke hōʻemi i ka hoʻokaʻawale i ka metabolic o nā mea i hoʻokaʻawale e nā isoenzymes o ka cytochrome P450, hiki i ka hopena o ke kāohi ʻana o GR. I ka hiki ʻole ke hoʻokaʻawale i nā hopena like o octreotide, nā lāʻau lapaʻau e hoʻoliʻohui e nā isoenzymes o ka ʻōnaehana cytochrome P450 a loaʻa iā lākou kahi ākea terapeutic kūʻokoʻa (quinidine a me terfenadine) e kuhikuhi me ka akahele.

ʻO ka maʻi maʻi o ka endocrine o ka gastrointestinal tract a me ka pancreas

No nā poʻe maʻi e hoʻohana nei i ka octreot pōkole hana kūpono i ka ʻohi o nā hōʻailona o ka maʻi, ka hopena mua o ka lāʻau lapaʻau he 20 mg i kēlā me kēia 4 pule. Eia nō hoʻi, ma hope o ka hoʻomaka ʻana o ka hoʻokele waiwai o Octreotide-depot, hoʻomau ʻia ka hoʻohana ʻana o ka octreotide i ʻāʻemu mau no 2 mau pule.

No nā poʻe maʻi i loaʻa ʻole i ka sperm octreotide, pono e mālama ʻia ka mea lapaʻau e hoʻomaka me ke ʻano lāʻau o ka lāʻau no ka s / c hoʻokō ma kahi wai o 0.1 mg 3 mau manawa i ka lā no kahi mau he 2 wiki. Pono kēia e loiloi i kona kū pono a me ka ʻoluʻolu ʻē aʻe. Ma laila hiki wale nō ke hoʻohana ʻia ka Octreotide Depot e like me ka mea i hōʻike ʻia ma luna nei.

Inā ma hope o 3 mau malama o ka mālama ʻana i hoʻokō ʻia wale nō ka mea i hoʻokō ʻia, Octreotide Depot 30 mg i kēlā me kēia mau 4 wiki. I loko o nā hihia i loko o 3 mau mahina o ka lapaʻau hiki ke hiki i ka lawa o ka hoʻomohala ʻana o nā hōʻike lapaʻau a me nā hōʻailona olakino, hiki ke hōʻemi ʻia ka nui i ka 10 mg i kēlā me kēia 4 hebedoma.

E pale aku i ke ʻano o ka hoʻohana ʻana o Octreotide-depot i kekahi mau lā (ʻoi aku ma ka 2 mau mahina mua o ka mālama ʻana, a hiki i ka hopena therapeutic plasma o nā mea ikaika e hana nei), ke ʻano ʻike o nā kauka maʻi endocrine tumors o ka gastrointestinal tract a me ka pancreas e hoʻonui. Hoʻokomo ʻia kēlā mau mea maʻi e hoʻohui pū i ka sperm octreotide i kahi pāʻina i kuhikuhi ʻia ma mua o ka hoʻomaka ʻana o Octreotide Depot.

Inā ʻo nā mea huna a me ka hū ʻole ʻole ʻia o nā ʻōpū neuroendocrine maʻamau o ke kolone, ʻoi aku ke kihi, ileum, makapō, jejunum a me ka hoʻopili ʻana, me nā metastases o nā mea kūleʻa neuroendocrine e ʻole i ka manaʻo nui, ua kuhikuhi ʻia ʻo Octreotide-depot ma loko o kahi waihona no 30 mg kēlā me 4 wiki. Hoʻomau ka Therapy a hiki ke hoʻomālamalama ʻia ke kiko (a ʻike ʻia nā hōʻailona o kona neʻe ʻana).

ʻO ka hopena o ka maʻi prostate e pale aku ana

ʻO ka maʻa mua ʻapōpō ʻo Octreotide Depot he 20 mg i kēlā me 4 wiki no 3 mahina. I ka wā e hiki mai ana, hoʻoponopono ke kauka i ka ʻokoʻa ma muli o nā hōʻike kino o ka maʻi a me ka hoʻoili ʻana o nā ʻano antigen prostatic kūikawā i loko o ka serum koko.

Inā ma loko o 3 mau malama o ka lapaʻau, ʻaʻole hiki i ka hoʻokō kūpono ʻana o nā maʻi lapaʻau o nā maʻi a me nā mea hōʻailona koiola (hoʻemi ʻia ka PSA), hoʻonui ʻia ka nui i ka 30 mg i kēlā me 4 wiki.

Hoʻohana ʻo Octreotide-depot i ka hui pū me ka dexamethasone i hoʻohana ʻia i loko o ka waha o ka waha ʻōlelo e like me ke ʻano i hōʻike ʻia: 4 mg / lā no 1 mahina, a laila 2 mg / lā no 2 mau pule, a ma hope iho he 1 mg / lā.

I nā mea maʻi i loaʻa mua i ka lāʻau antiandrogen therapy, ua hui pū ʻia ka hui me Octreotide-Depot + Dexamethasone me ka hoʻohana ʻana o ka mea kuʻina o ka gonadotropin-hoʻokuʻu i ka hormone o nā form depot, i hoʻohālikelike ʻia i hoʻokahi manawa i kēlā me kēia 4 hebedoma.

ʻO kēlā me kēia mahina i ka mālama ʻana, pono e hoʻoholo i ke kāʻei o PSA.